Multivalent pneumococcal polysaccharide-protein conjugate compositions

By developing mixed carriers, multivalent pneumococcal conjugate compositions, using CRM197 and tetanus toxoid combined with aluminum-based adjuvant, the problems of insufficient effect of existing vaccines in the elderly and infants and insufficient serotype coverage are solved. , achieving strong immune protection against a variety of pneumococcal types.

CN118903402APending Publication Date: 2024-11-08SANOFI PASTEUR INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411035063.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-04-18
Filing Date
2019-02-04
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing pneumococcal vaccines are not effective in infants and elderly people who lack a developed immune system, especially in developing countries at high risk, and existing vaccines fail to effectively cover all pneumococcal serotypes, leading to disease Increase.

Method used

A hybrid carrier, multivalent pneumococcal conjugate composition was developed, containing 21 different pneumococcal capsular polysaccharide-protein conjugates, using CRM197 and tetanus toxoid as carrier proteins, combined with aluminum-based adjuvants, Used to prevent Streptococcus pneumoniae infection.

Benefits of technology

The immune response to a variety of pneumococcal serotypes is significantly improved, especially to uncovered serotypes such as 9N, 8, 10A, 11A, 12F, 15B, 22F and 33F, enhancing the antibody response to these types, Provides a wider range of protective immunity effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004970855330000351
    Figure BDA0004970855330000351
  • Figure BDA0004970855330000401
    Figure BDA0004970855330000401
  • Figure BDA0004970855330000411
    Figure BDA0004970855330000411
Patent Text Reader

Abstract

Provided are mixed carriers, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates wherein each of the conjugates comprises a capsular polysaccharide from a different Streptococcus pneumoniae serotype conjugated to a tetanus toxoid (TT) or CRM197 wherein the Streptococcus pneumoniae serotype is selected from the group consisting of 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein said capsular polysaccharides of two of serotypes 1, 3 and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions, and methods of using the compositions to prevent Streptococcus pneumoniae infection or disease in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention is a divisional application of a case with a filing date of February 4, 2019, an application number of 201980011404.1, and an invention name of “Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of and relies on the filing dates of U.S. Provisional Patent Application No. 62 / 626,509, filed on February 5, 2018, and Korean Patent Application No. 10-2018-0045246, filed on April 18, 2018, the entire disclosures of which are incorporated herein by reference. Technical Field

[0004] The present application generally relates to mixed carriers, multivalent pneumococcal conjugate compositions, vaccines comprising the compositions, and methods for using these compositions and vaccines for preventing Streptococcus pneumoniae infection or disease in a subject. Background Art

[0005] The pneumococcus (S. pneumoniae) is a Gram-positive, lancet-shaped, facultative anaerobic bacterium with over 90 known serotypes. Most S. pneumoniae serotypes have been shown to cause disease, with the 23 most common serotypes causing approximately 90% of invasive disease worldwide. Serotypes are classified based on serological responses to the capsular polysaccharide, the most important virulence factor of the pneumococcus. The capsular polysaccharide is a T-cell-independent antigen that induces antibody production in the absence of T helper cells. T-cell-independent antigens typically induce low-affinity antibodies and short-lived immune responses with little to no immunological memory.

[0006] Initial pneumococcal vaccines include combinations of capsular polysaccharides from different serotypes. These vaccines can confer immunity against S. pneumoniae in patients with a developed or healthy immune system, however, they are ineffective in infants who lack a developed immune system and elderly subjects who are generally immunocompromised. In order to improve the immune response of pneumococcal vaccines, especially in infants and elderly subjects who are at a higher risk of developing S. pneumoniae infection, capsular polysaccharides are conjugated to suitable carrier proteins to produce pneumococcal conjugate vaccines. Conjugation with suitable carrier proteins changes capsular polysaccharides from T cell-independent antigens to T cell-dependent antigens. Specifically, the immune response against conjugated capsular polysaccharides involves T helper cells, which assist in inducing a more powerful and rapid immune response when re-exposed to capsular polysaccharides.

[0007] There are at least two approaches to developing pneumococcal conjugate vaccines: the single carrier approach and the mixed carrier approach. The immunogenicity of different capsular polysaccharide conjugates can vary depending on the pneumococcal serotype and carrier protein used. In the single carrier approach, capsular polysaccharides from different serotypes are conjugated to a single protein carrier. 197 An example of a single carrier approach with conjugation to a protein carrier (a nontoxic variant of diphtheria toxoid with a single amino acid substitution of glycine for glutamic acid) is Pfizer's Prevnar series of vaccines. The 7-valent Prevnar vaccine (PREVNAR) was first approved in 2000 and contains capsular polysaccharides from the 7 most prevalent serotypes: 4, 6B, 9V, 14, 18C, 19F, and 23F. The 13-valent vaccine, PREVNAR 13, adds serotypes 1, 5, 7F, 3, 6A, and 19A to the CRM. 197 Protein carrier. The single carrier used in PREVNAR vaccine, protein carrier CRM 197 , has never been used as part of a mixed carrier system for pneumococcal conjugate vaccines.

[0008] The second pneumococcal vaccine approach is the mixed carrier approach. In the mixed carrier approach, two or more protein carriers are used instead of a single protein carrier, wherein the capsular polysaccharide from a particular serotype is conjugated to a first protein carrier and the capsular polysaccharide from a different serotype is conjugated to at least a second, different protein carrier. For example, GlaxoSmithKline has developed SYNFLORIX, a 10-valent (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F), mixed carrier, pneumococcal conjugate vaccine that uses Haemophilus influenzae protein D, tetanus toxoid and diphtheria toxoid as protein carriers. In SYNFLORIX, serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F are conjugated to protein D; serotype 18C is conjugated to tetanus toxoid; and serotype 19F is conjugated to diphtheria toxoid [2]. Serotype 3 was partially removed from the 11-valent precursor to become diflubenzuron because the serotype 3 did not show serotype-specific efficacy in the acute otitis media test [1]. Another group, Aventis Pasteur, developed an 11-valent (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F), mixed carrier, pneumococcal conjugate vaccine using diphtheria toxoid and tetanus toxoid as protein carriers [3]. Capsular polysaccharides from serotypes 3, 9V, 14 and 18C can cause a better response when conjugated to diphtheria toxoid than when conjugated to tetanus toxoid [6]. Therefore, serotypes 3, 6B, 14 and 18C are conjugated to diphtheria toxoid and serotypes 1, 4, 5, 7F, 9V, 19F and 23F are conjugated to tetanus toxoid. Development of this mixed vector, pneumococcal vaccine was discontinued, in part due to technical factors and reduced reactivity potential when administered with acellular pertussis vaccines [3]. Recently, serotypes 5 and 1 were reported to have one of the lowest OPA titers observed for all PREVNAR 13 serotypes, with a correlation between IgG titers and OPA activity [4]. It has also been suggested that for serotype 3, protection would require much higher serum IgG concentrations [5]. Summary of the invention

[0009] The present application provides new and improved mixed carriers, multivalent pneumococcal conjugate compositions, and vaccines comprising the compositions. In one aspect, the mixed carrier, multivalent pneumococcal conjugate composition comprises 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different pneumococcal serotype, wherein the pneumococcal serotype is selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein the protein carrier is CRM 197 or tetanus toxoid, wherein four of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 conjugated, and wherein two of the four capsular polysaccharides conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3 and 5, and the remaining two capsular polysaccharides are serotypes 15B and 22F.

[0010] In one embodiment of a mixed carrier, 21-valent pneumococcal conjugate composition, capsular polysaccharides from serotypes 1, 5, 15B, and 22F are conjugated to tetanus toxoid, and capsular polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM 197 Conjugation.

[0011] In another embodiment of the mixed carrier, 21-valent pneumococcal conjugate composition, capsular polysaccharides from serotypes 1, 3, 15B and 22F are conjugated to tetanus toxoid, and capsular polysaccharides from serotypes 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F and 33F are conjugated to CRM 197 Conjugation.

[0012] In another embodiment of the mixed carrier, 21-valent pneumococcal conjugate composition, capsular polysaccharides from serotypes 3, 5, 15B and 22F are conjugated to tetanus toxoid, and capsular polysaccharides from serotypes 1, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F and 33F are conjugated to CRM 197 Conjugation.

[0013] In another aspect, the present application provides a mixed carrier, multivalent pneumococcal conjugate composition comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different S. pneumoniae serotype, wherein the S. pneumoniae serotype is selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, wherein the protein carrier is CRM. 197 or tetanus toxoid, wherein three of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 Conjugated, and wherein the three capsular polysaccharides conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, 5, 15B and 22F. In certain embodiments, two of the three capsular polysaccharides conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3 and 5, and the remaining capsular polysaccharide conjugated to tetanus toxoid is serotype 15B or 22F.

[0014] In some embodiments, the mixed carrier, multivalent pneumococcal conjugate composition further comprises an adjuvant, such as an aluminum-based adjuvant, including but not limited to aluminum phosphate, aluminum sulfate, and aluminum hydroxide.

[0015] Another aspect relates to the use of the mixed carrier, 21-valent pneumococcal conjugate composition as a vaccine.

[0016] Another aspect relates to a vaccine comprising a mixed carrier, a 21-valent pneumococcal conjugate composition and a pharmaceutically acceptable excipient.

[0017] Another aspect relates to a method for preventing S. pneumoniae infection or disease in a subject, such as a human, comprising administering to the subject a prophylactically effective amount of a mixed vector, a 21-valent pneumococcal conjugate composition, or a vaccine comprising the composition.

[0018] In certain embodiments, the subject is a human who is at least 50 years old and the disease is pneumonia or invasive pneumococcal disease (IPD).

[0019] In other embodiments, the subject is a human of at least 6 weeks old and the disease is pneumonia, invasive pneumococcal disease (IPD) or acute otitis media (AOM). In some embodiments, the human subject is 6 weeks to 5 years old. In other embodiments, the human subject is 2 to 15 months or 6 to 17 years old.

[0020] In certain embodiments, the mixed vector, 21-valent pneumococcal conjugate composition or vaccine is administered by intramuscular injection. In certain embodiments, the mixed vector, 21-valent pneumococcal conjugate composition or vaccine is administered as part of an immunization series.

[0021] Another aspect relates to an immunogenic conjugate of Streptococcus pneumoniae serotype 9N, comprising: a serotype 9N capsular polysaccharide from Streptococcus pneumoniae; and a carrier protein bound to the capsular polysaccharide, wherein the carrier protein is a CRM 197 In certain embodiments of the immunogenic serotype 9N conjugates, the mixed carriers, the multivalent pneumococcal conjugate compositions and vaccines (and methods / uses thereof), the serotype 9N polysaccharide may be conjugated to the CRM 197 The state of the serotype 9N polysaccharide is activated, has an oxidation degree of 2-19 or 5-10, and a molecular weight of 200-700 kDa. In certain embodiments of the immunogenic serotype 9N conjugate, the mixed carrier, the multivalent pneumococcal conjugate composition and the vaccine (and methods / uses thereof), the immunogenic serotype 9N conjugate may have a molecular weight of 500-4,000 kDa.

[0022] In certain embodiments of the immunogenic serotype 9N conjugate, the mixed carrier, the multivalent pneumococcal conjugate composition and vaccine (and methods / uses thereof), the ratio of serotype 9N capsular polysaccharide to carrier protein in the serotype 9N immunogenic conjugate is 0.1-5 (w / w). In certain embodiments, the ratio is 0.5-2.5.

[0023] In certain embodiments of the immunogenic serotype 9N conjugate, the mixed carrier, the multivalent pneumococcal conjugate composition and vaccine (and methods / uses thereof), 15-60% of the immunogenic serotype 9N conjugate may have a K of 0.3 or less in a CL-4B column. d .

[0024] In certain embodiments of the immunogenic serotype 9N conjugate, the hybrid carrier, the multivalent pneumococcal conjugate composition and vaccine (and methods / uses thereof), the immunogenic serotype 9N conjugate has been prepared with a serotype 9N polysaccharide that has been activated to achieve a degree of oxidation of 2-19. In certain embodiments, the immunogenic serotype 9N conjugate has been prepared with a serotype 9N polysaccharide that has been activated to achieve a degree of oxidation of 5-10.

[0025] In certain embodiments of the immunogenic serotype 9N conjugate, the mixed carrier, the multivalent pneumococcal conjugate composition and vaccine (and methods / uses thereof), when the pneumococcal serotype 9N saccharide is conjugated to the CRM by adding 0.02-0.19 μg of periodate per 1 μg of saccharide, 197 When conjugated, the conjugate may have a molecular weight of 500-4,000 kDa, a molecular weight distribution (K d ≤0.3) and a sugar / protein ratio of 0.5-2.5.

[0026] In another aspect, the present disclosure also provides a method for preparing an immunogenic conjugate of Streptococcus pneumoniae serotype 9N, the method comprising:

[0027] (a) lysing bacterial cells which produce Streptococcus pneumoniae serotype 9N capsular polysaccharide by fermentation;

[0028] (b) purifying S. pneumoniae serotype 9N capsular saccharides from lysed cells;

[0029] (c) activating the S. pneumoniae serotype 9N capsular polysaccharide by reacting it with an oxidizing agent to achieve a degree of oxidation of 2-19 or 5-10; and

[0030] (d) By combining the activated sugar with CRM 197 Mixed to form Streptococcus pneumoniae serotype 9N capsular saccharide and CRM 197 Bound conjugate.

[0031] In certain embodiments, the CRM mixed in step (d) 197 Can react with a reducing agent to form a conjugate with activated S. pneumoniae serotype 9N capsular polysaccharide. In certain embodiments, in step (c), 0.02-0.19 μg of periodate can react with 1 μg of S. pneumoniae serotype 9N capsular polysaccharide at 20-25°C for 15-20 hours.

[0032] In certain embodiments, the pneumococcal serotype 9N capsular polysaccharide reacted with the oxidizing agent in step (c) may have a molecular weight of 400-900 kDa. In certain embodiments, the pneumococcal serotype 9N capsular polysaccharide reacted with the oxidizing agent in step (d) may have a molecular weight of 400-900 kDa. 197 The mixed activated S. pneumoniae serotype 9N capsular polysaccharide may have a molecular weight of 200-700 kDa. In certain embodiments, the immunogenic conjugate of S. pneumoniae serotype 9N may have a molecular weight of 500-4,000 kDa. In certain embodiments, the CRM 197 The initial input ratio of activated serotype 9N capsular saccharide (carrier CRM 197In some embodiments, at least 15-60% of the immunogenic conjugates may have a K of 0.3 or less as measured in a CL-4B column. d .

[0033] In certain embodiments, when the S. pneumoniae serotype 9N polysaccharide of the present disclosure is combined with CRM by adding 0.02-0.19 μg of periodate per 1 μg of sugar, 197 When conjugated, the immunogenic conjugate had a molecular weight of 500-4,000 kDa, a molecular weight distribution (K d ≤0.3) and CRM of 0.5-2.5 197 / polysaccharide ratio.

[0034] The foregoing and other objects, features and advantages of the mixed carrier, 21-valent pneumococcal conjugate composition will become more apparent from the following detailed description.

[0035] definition

[0036] In order to more easily understand the present disclosure, certain terms are first defined as follows. Additional definitions of the following terms and other terms may be set forth in this specification.

[0037] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a method" includes one or more methods described herein, and / or steps of the type and / or those that will become apparent to those skilled in the art upon reading this disclosure, and so forth.

[0038] Administration: As used herein, "administering" a composition to a subject means giving, applying, or contacting the composition to a subject. Administration can be accomplished by any of a variety of routes, such as topical, oral, subcutaneous, intramuscular, intraperitoneal, intravenous, intrathecal, and intradermal.

[0039] Approximately: As used herein, the term "approximately" or "about", when used for one or more numerical values ​​of interest, refers to a value similar to the reference value. In certain embodiments, the term "approximately" or "about" refers to a value falling within a range of 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (greater than or less than) of the reference value, unless otherwise stated or understood from the context (except that this number will exceed 100% of the possible value).

[0040] Conjugate: As used herein, and as understood from the appropriate context, the term "conjugate" or "glycoconjugate" refers to a S. pneumoniae polysaccharide conjugated to a carrier protein using any covalent or non-covalent bioconjugation strategy.

[0041] Oxidation degree: As used herein, the term "degree of oxidation" (DO) refers to the number of sugar repeating units produced per aldehyde group when purified or size-fractionated sugars are activated with an oxidizing agent. The degree of oxidation of sugars can be determined using conventional methods known to those of ordinary skill in the art.

[0042] Excipient: As used herein, the term "excipient" refers to a non-therapeutic agent that may be included in a composition, for example, to provide or promote desired consistency or stabilization.

[0043] Mixed carrier: As used herein, mixed carrier, pneumococcal conjugate composition refers to a pneumococcal conjugate composition having more than one type of protein carrier.

[0044] Multivalent: As used herein, the term "multivalent" refers to a pneumococcal conjugate composition having pneumococcal capsular polysaccharides from more than one S. pneumoniae serotype.

[0045] Mixed carrier, 21-valent pneumococcal conjugate composition: As used herein, the term "mixed carrier, 21-valent pneumococcal conjugate composition" refers to a composition comprising or consisting of 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different S. pneumoniae serotype, wherein the S. pneumoniae serotype is 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, and wherein the protein carrier is CRM. 197 or tetanus toxoid, wherein 1) three of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 conjugated to tetanus toxoid and wherein two of the three capsular polysaccharides conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3 and 5 and the remaining capsular polysaccharide is serotype 15B or 22F; or 2) wherein four of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharide is conjugated to CRM 197Conjugated, and wherein two of the four capsular polysaccharides conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5, and the remaining two capsular polysaccharides are serotypes 15B and 22F. In some embodiments, capsular polysaccharides from serotypes 1, 5, 15B, and 22F are conjugated to tetanus toxoid, and the remaining capsular polysaccharides are conjugated to CRM 197 In another embodiment, capsular polysaccharides from serotypes 1, 3, 15B, and 22F are conjugated to tetanus toxoid, and capsular polysaccharides from the remaining serotypes are conjugated to CRM 197 In another embodiment, capsular polysaccharides from serotypes 3, 5, 15B, and 22F are conjugated to tetanus toxoid, and the remaining capsular polysaccharides are conjugated to CRM 197 Conjugation.

[0046] Molecular weight: As used herein, unless otherwise indicated, the term "molecular weight" of a capsular saccharide or capsular saccharide-carrier protein conjugate refers to the average molecular weight calculated by size exclusion chromatography (SEC) in combination with multi-angle laser light scattering (MALLS).

[0047] Pharmaceutically acceptable excipients: pharmaceutically acceptable excipients available in the present disclosure are commonly used. EW Martin, Mack Publishing Co., Easton, PA, Remington's Pharmaceutical Sciences, 15th edition (1975) describes compositions and preparations suitable for pharmaceutical delivery of one or more therapeutic compositions, including vaccines, and other medicaments. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talcum powder, sodium chloride, dried skim milk, glycerol, propylene (propylene), glycol, water, ethanol, etc. In general, the properties of the excipient will depend on the specific mode of administration used. For example, parenteral preparations generally contain injectable fluids, including pharmaceutically and physiologically acceptable fluids, such as water, saline, balanced salt solutions, buffers, aqueous dextrose, glycerol, etc. as vehicles. For solid compositions (e.g., powder, pill, tablet or capsule form), commonly used non-toxic solid excipients may include, for example, pharmaceutical grade mannitol, lactose, starch or magnesium stearate. In addition to biologically neutral carriers, the pharmaceutical composition to be administered may contain small amounts of non-toxic auxiliary substances, such as wetting agents or emulsifiers, surfactants, preservatives and pH buffers, etc., for example sodium acetate or sorbitan monolaurate.

[0048] Prophylactically effective amount: As used herein, the term "prophylactically effective amount" or "prophylactically effective dose" refers to the amount or dose required to induce an immune response sufficient to delay the onset and / or reduce the frequency and / or severity of one or more symptoms caused by S. pneumoniae infection.

[0049] Prevention: As used herein, the term "prevention" refers to avoiding disease manifestation, delaying onset, and / or reducing the frequency and / or severity of one or more symptoms of a particular disease, disorder, or condition (e.g., pneumococcal infection). In some embodiments, prevention is assessed on a population basis, such that if a statistically significant decrease in the development, frequency, and / or intensity of one or more symptoms of the disease, disorder, or condition is observed in a population susceptible to the disease, disorder, or condition, then the agent is considered to provide prevention for the particular disease, disorder, or condition.

[0050] Subject: As used herein, the term "subject" refers to any mammal, including mice, rabbits, and humans. In certain embodiments, the subject is an adult, a teenager, or an infant. In some embodiments, the term "individual" or "patient" is used and is intended to be interchangeable with "subject." DETAILED DESCRIPTION

[0051] The following description of the disclosed embodiments and examples is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.

[0052] The present application provides new and improved mixed carriers, multivalent pneumococcal conjugate compositions and vaccines comprising the same. 197 It has been used previously in single-vector, pneumococcal conjugate vaccines, but this application describes CRM 197 Use in mixed carriers, pneumococcal conjugate vaccines. In particular, the present application describes CRM 197 Combined use of tetanus toxoid and tetanus toxoid as carrier proteins for specific pneumococcal serotypes in multivalent pneumococcal conjugate compositions and vaccines.

[0053] As discussed above, the immunogenicity of different capsular polysaccharide conjugates may vary depending on the pneumococcal serotype and carrier protein used. The present application describes the successful conjugation of serotype 3 with tetanus toxoid as part of a mixed carrier vaccine, despite previous teachings that serotype 3 is more immunogenic when conjugated to diphtheria toxoid rather than tetanus toxoid [6]. The present application also describes the successful conjugation of serotypes 1, 5, 15B and 22F with tetanus toxoid as part of a mixed carrier vaccine. The unexpected discovery is also disclosed that the antibody response to serotype 3 conjugated to tetanus toxoid in a mixed carrier, multivalent, e.g., 21-valent, pneumococcal conjugate composition is greater than that to serotype 3 conjugated to CRM in a single carrier, 13-valent pneumococcal conjugate composition (Prevnar 13). 197 It was about 4.5 times higher when conjugated.

[0054] Additionally, the unexpected findings were not limited to serotype 3, but were also observed for other serotypes conjugated to tetanus toxoid in mixed carrier, multivalent pneumococcal conjugate compositions. For example, as shown in the Examples, conjugation to CRM in a single carrier, pneumococcal conjugate composition (Prevnar 13) was not limited to serotype 3, but was also observed for other serotypes conjugated to tetanus toxoid in mixed carrier, multivalent pneumococcal conjugate compositions. 197 The antibody response (IgG response or MOPA titer) of the same serotype conjugated to the mixed carrier, pneumococcal conjugate composition in which serotypes 1 and 5 or 3 and 5 were conjugated to tetanus toxoid and the remaining serotypes were conjugated to CRM 197 The conjugations (eg, PCV21(1 / 5 / 15B / 22F)-TT and PCV21(3 / 5 / 15B / 22F)-TT) consistently induced significantly enhanced antibody responses to serotypes conjugated to tetanus toxoid.

[0055] Tetanus toxoid is significantly greater than CRM 197 Thus, conjugating three or four of the serotypes 1, 3, 5, 15B and 22F to tetanus toxoid as part of a mixed vector vaccine results in a vaccine that is comparable to conjugating to a single vector smaller than tetanus toxoid, such as CRM. 197 The polysaccharide to carrier ("PS / C") ratio of those serotypes conjugated to tetanus toxoid is reduced compared to the PS / C ratios of those same serotypes of tetanus toxoid. In this way, the mixed carrier method described in this application can be used to reduce the PS / C ratio of one or more of serotypes 1, 3, 5, 15B or 22F.

[0056] The mixed carrier, 21-valent pneumococcal conjugate compositions described in the present application also include three pneumococcal conjugate vaccines currently available on the global market: PREVNAR (known as Prevenar in some countries), SYNFLORIX and PREVNAR 13, pneumococcal serotypes not currently covered. Diseases caused by pneumococcal serotypes not currently covered are on the rise, in part due to the development of antibacterial resistance, the increase in the number of immunocompromised patients, and the lack of immune pressure. For example, none of the currently available pneumococcal conjugate vaccines include serotype 9N. In addition, none of the currently available pneumococcal conjugate vaccines include serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F. The present disclosure demonstrates the successful provision of serotypes 8, 9N, 10A, 11A, 12F, 15B, 22F and 33F into a mixed carrier (tetanus toxoid and CRM 197 ) pneumococcal conjugate vaccines, and serotype 9N induced an antibody response approximately 40 to 50 times higher than that of Prevnar 13.

[0057] Pneumococcal polysaccharide serotype 9N

[0058] Serotype 9N polysaccharides can be obtained directly from bacteria using isolation procedures known to those skilled in the art, including but not limited to the methods disclosed in US Patent Application Publication No. 2006 / 0228380. In addition, the saccharides can be produced using synthetic protocols.

[0059] Serotype 9N S. pneumoniae strains can be obtained from established culture collections (e.g., the Streptococcal Reference Laboratory of the Centers for Disease Control and Prevention (Atlanta, Georgia)) or from clinical specimens.

[0060] Bacterial cells are typically grown in a culture medium, such as a soy-based culture medium. After fermentation of bacterial cells producing serotype 9N capsular polysaccharides of Streptococcus pneumoniae, the bacterial cells are lysed to produce a cell lysate. Then, the serotype 9N polysaccharide can be separated from the cell lysate using purification techniques known in the art, including centrifugation, depth filtration, precipitation, ultrafiltration, activated carbon treatment, diafiltration and / or column chromatography (including but not limited to the methods disclosed in U.S. Patent Application Publication No. 2006 / 0228380). The purified serotype 9N capsular polysaccharide can be used to prepare an immunogenic conjugate. The serotype 9N capsular polysaccharide obtained by purifying the serotype 9N polysaccharide from the lysate of Streptococcus pneumoniae and optionally fractionating the purified polysaccharide particle size can be characterized by different parameters, including, for example, the molecular weight (MW) of the serotype 9N capsular polysaccharide.

[0061] In certain embodiments, the purified polysaccharide purified from S. pneumoniae serotype 9N has a molecular weight of 5-5,000 kDa before conjugation. In certain embodiments, the serotype 9N capsular polysaccharide has a molecular weight of 50-1,000 kDa before conjugation. In certain embodiments, the serotype 9N capsular polysaccharide has a molecular weight of 70-900 kDa before conjugation. In certain embodiments, the serotype 9N capsular polysaccharide has a molecular weight of 100-800 kDa before conjugation. In certain embodiments, the purified serotype 9N capsular polysaccharide may be activated prior to conjugation to have a molecular weight of 50-800 kDa, 80-780 kDa, 100-770 kDa, 120-760 kDa, 140-750 kDa, 150-740 kDa, 160-730 kDa, 170-735 kDa, 180-720 kDa, 190-710 kDa, 200-700 kDa, 220-690 kDa, 240-680 kDa, 260-670 kDa, 270-660 kDa or similar molecular weight ranges. Any integer within any one of the above ranges is contemplated as an embodiment of the present disclosure.

[0062] The activated serotype 9N polysaccharide can be characterized by the degree of oxidation and molecular weight. In certain embodiments, the activated serotype 9N polysaccharide can have a degree of oxidation of 0.5-25, 0.6-23, 0.8-21, 1-20.8, 1.1-20.5, 1.2-20.3, 1.3-20, 1.4-19.5, 1.5-19.3, 1.6-19.2, 1.7-19.12-19, 3-18, 4-15, or 5-10.

[0063] The size of the polysaccharide may be slightly reduced during normal purification procedures. In addition, as described in the present disclosure, the polysaccharide may be subjected to size fractionation prior to conjugation. The molecular weight ranges mentioned above refer to the molecular weight ranges of the purified polysaccharide after the final size fractionation step prior to conjugation (e.g., after purification, hydrolysis, and activation).

[0064] Mixed carrier, multivalent pneumococcal conjugate composition and preparation method thereof

[0065] The present disclosure provides a mixed carrier, multivalent pneumococcal conjugate composition comprising or consisting of 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different S. pneumoniae serotype, wherein the S. pneumoniae serotypes are 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein the protein carrier is CRM 197 or tetanus toxoid, wherein 3-4 of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 Conjugated, and wherein the 3-4 capsular polysaccharides conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, 5, 15B and 22F. In certain embodiments, three of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 In certain embodiments, four of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharide is conjugated to CRM 197 Conjugation.

[0066] In some aspects, the present disclosure provides a mixed carrier, multivalent pneumococcal conjugate composition comprising or consisting of 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different S. pneumoniae serotype, wherein the S. pneumoniae serotype is 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein the protein carrier is CRM. 197 or tetanus toxoid, wherein four of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 conjugated, and wherein two of the four capsular polysaccharides conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3 and 5, and the remaining two capsular polysaccharides are serotypes 15B and 22F.

[0067] In one embodiment, capsular polysaccharides from serotypes 1, 5, 15B, and 22F are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 In another embodiment, capsular polysaccharides from serotypes 1, 3, 15B, and 22F are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 In another embodiment, capsular polysaccharides from serotypes 3, 5, 15B, and 22F are conjugated to tetanus toxoid, and the remaining capsular polysaccharides are conjugated to CRM 197 Conjugation.

[0068] In polysaccharide-protein conjugate vaccines, a carrier protein is conjugated to a polysaccharide antigen primarily to help increase the immune response (e.g., antibody response) to the polysaccharide antigen. The carrier protein is preferably non-toxic. The carrier protein should be able to withstand conjugation with pneumococcal polysaccharides using standard conjugation procedures, as discussed in more detail below. The carrier protein used in the mixed carrier, 21-valent pneumococcal conjugate composition is tetanus toxoid (TT) and CRM 197 , each of which has been used in the design of pneumococcal conjugate vaccines, but never in the same, mixed vector vaccine.

[0069] CRM 197 A non-toxic variant of diphtheria toxin (ie, toxoid) that retains the immunological properties of wild-type diphtheria toxin. 197 The difference from wild-type diphtheria toxin is a single base in the structural gene, which results in a single amino acid substitution from glutamic acid to glycine. 197 It is usually isolated from cultures of Corynebacterium diphtheria strain C7 (β197) grown on a casamino acid and yeast extract based medium. 197 Purification can be performed by ultrafiltration, ammonium sulfate precipitation, and ion exchange chromatography. Alternatively, CRM 197 Can be recombinantly prepared according to U.S. Patent No. 5,614,382, which is hereby incorporated by reference in its entirety. 197 It has been used in the design of pneumococcal conjugate vaccines, but never as part of a mixed vector vaccine.

[0070] Tetanus toxoid is prepared and used worldwide for large-scale immunization against tetanus (or lockjaw) caused by Clostridium tetani. Tetanus toxoid is also used alone and in combination with diphtheria and / or pertussis vaccines. The parent protein, tetanus toxin, is typically obtained from cultures of Clostridium tetani. Tetanus toxin is a protein of approximately 150 kDa and consists of two subunits (approximately 100 kDa and approximately 50 kDa) linked by a disulfide bond. The toxin is typically detoxified with formaldehyde and can be purified from culture filtrates using known methods, such as ammonium sulfate precipitation (see, e.g., [7], [8]) or chromatographic techniques, as disclosed, e.g., in WO 1996 / 025425. Tetanus toxin can also be inactivated by recombinant genetic means.

[0071] Tetanus toxoid has also been used as a carrier protein in other vaccines, including pneumococcal conjugate vaccines. 197 The combination for use in a mixed carrier, pneumococcal conjugate vaccine is novel. There is also contrary teaching in the art regarding conjugation of serotype 3 to tetanus toxoid in a mixed carrier, pneumococcal conjugate vaccine, as it was shown that serotype 3 is more immunogenic when conjugated to diphtheria toxoid compared to tetanus toxoid [6].

[0072] Pneumococcal capsular polysaccharides used in the compositions and vaccines described herein, including capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, can be prepared from S. pneumoniae using any available technology, including standard techniques known to those of ordinary skill in the art, including, for example, WO 2006 / 110381, WO 2008 / 118752, WO 2009 / 119498, WO 2010 / 119499, WO 2011 / 119491, WO 2012 / 119495, WO 2013 / 119496, WO 2014 / 119497, WO 2015 / 119498, WO 2016 / 119499, WO 2017 / 119498, WO 2018 / 119499, WO 2019 / 119491, WO 2020 2006 / 110352 and those disclosed in U.S. Patent Application Publication Nos. 2006 / 0228380, 2006 / 0228381, 2007 / 0184071, 2007 / 0184072, 2007 / 0231340, 2008 / 0102498 and 2008 / 0286838, all of which are incorporated by reference in their entirety. For example, each pneumococcal polysaccharide serotype can be grown in a culture medium (e.g., a soy-based culture medium). The cells are lysed, and individual polysaccharides can be purified from the lysate by centrifugation, precipitation, ultrafiltration and / or column chromatography. In addition, pneumococcal capsular polysaccharides can be produced using synthetic procedures.

[0073] The capsular polysaccharide of Streptococcus pneumoniae comprises repeated oligosaccharide units, which may comprise up to 8 saccharide residues. The capsular saccharide antigen may be a full-length polysaccharide, or it may be reduced in size (e.g., a single oligosaccharide unit, or a shorter sugar chain than the native length of the repeating oligosaccharide unit). The size of the capsular polysaccharide may be reduced by various methods known in the art, such as acid hydrolysis treatment, hydrogen peroxide treatment, particle size fractionation by a high pressure homogenizer, optionally followed by hydrogen peroxide treatment to produce oligosaccharide fragments, or microfluidization technology.

[0074] Pneumococcal conjugates of each serotype can be prepared by conjugating the capsular polysaccharide of each serotype to a carrier protein. The different pneumococcal conjugates can be formulated into compositions, including single-dose formulations.

[0075] In order to prepare polysaccharide-protein conjugates, the capsular polysaccharide prepared by each pneumococcal serotype can be chemically activated so that the capsular polysaccharide can react with the carrier protein. Once activated, each capsular polysaccharide can be conjugated with the carrier protein to form a glycoconjugate. The chemical activation of polysaccharides and the subsequent conjugation with the carrier protein can be achieved by conventional methods. For example, the ortho-hydroxyl groups at the ends of the capsular polysaccharide can be oxidized to aldehyde groups by oxidants such as periodates (including sodium periodate, potassium periodate or periodic acid), as disclosed in, for example, U.S. Patent Nos. 4,365,170, 4,673,574 and 4,902,506, which are hereby incorporated by reference in their entirety. Periodates randomly oxidize the ortho-hydroxyl groups of carbohydrates to form reactive aldehyde groups and cause C-C bond cleavage. The term "periodate" includes periodates and periodic acid. This term also includes metaperiodate (IO 4- ) and orthoperiodate (IO 65- ). The term "periodate" also includes various salts of periodate, including sodium periodate and potassium periodate. In certain embodiments, the polysaccharide can be oxidized in the presence of sodium metaperiodate.

[0076] In certain embodiments, periodate can be used in an amount of about 0.03-0.17 μg per 1 μg of polysaccharide. In certain embodiments, periodate can be used in an amount of about 0.025-0.18 μg or about 0.02-0.19 μg per 1 μg of polysaccharide. Sugar can be activated to the above range as needed. Beyond this range, the effect may be unsatisfactory.

[0077] The polysaccharide can also be activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then coupled to an amino group on a carrier protein directly or through a spacer or linker group.

[0078] For example, the spacer can be cystamine or cysteamine to obtain a thiolated polysaccharide, which can be coupled to the carrier through the resulting thioether bond after reaction with a maleimide-activated carrier protein (e.g., using N-[y-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl (4-iodoacetyl) aminobenzoate (S1AB), sulfonic acid succinimidyl (4-iodoacetyl) aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetylamino] propionate (SBAP)). Preferably, the cyanate ester (optionally prepared by COAP chemistry) is coupled with hexamethylenediamine or adipic acid dihydrazide (AOH), and the amino-derivatized sugar is conjugated to the carrier protein via the carboxyl groups on the protein carrier using carbodiimide (e.g., EDAC or EDC) chemistry. Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094, all of which are hereby incorporated by reference in their entirety.

[0079] The conjugation of the activated capsular polysaccharide and the carrier protein can be achieved, for example, by reductive amination, as described in, for example, U.S. Patent Application Publication Nos. 2006 / 0228380, 2007 / 0231340, 2007 / 0184071 and 2007 / 0184072, WO 2006 / 110381, WO 2008 / 079653 and WO 2008 / 143709, all of which are incorporated by reference in their entirety. For example, the activated capsular polysaccharide and the carrier protein can be reacted with a reducing agent to form a conjugate. Suitable reducing agents include borohydrides, such as sodium cyanoborohydride, borane-pyridine, sodium triacetoxyborohydride, sodium borohydride, or borohydride exchange resins. At the end of the reduction reaction, unreacted aldehyde groups may be present in the conjugate. Unreacted aldehyde groups can be capped using a suitable end-capping agent, such as sodium borohydride (NaBH 4 ) for end-capping. In one embodiment, the reduction reaction is carried out in an aqueous solvent. In another embodiment, the reaction is carried out in an aprotic solvent. In one embodiment, the reduction reaction is carried out in a DMSO (dimethyl sulfoxide) or DMF (dimethylformamide) solvent. Other possible reducing agents include, but are not limited to, amine boranes such as pyridine-borane, 2-methylpyridine-borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine-borane (PEMB).

[0080] The activated capsular polysaccharide can be conjugated directly to the carrier protein or indirectly by using a spacer or linker, such as a bifunctional linker. The linker is optionally heterobifunctional or homobifunctional, having, for example, a reactive amino group and a reactive carboxylic acid group, 2 reactive amino groups or 2 reactive carboxylic acid groups.

[0081] Other suitable conjugation techniques use carbodiimides, hydrazines, active esters, norboranes, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU, as described, for example, in International Patent Application Publication No. WO 98 / 42721, which is incorporated by reference in its entirety. Conjugation may involve a carbonyl linker, which may be formed by reacting the free hydroxyl groups of the sugar with 1,1'-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chem. 254: 2572-2574; Hearn et al. (1981) J. Chromatogr. 218: 509-518) followed by reaction with the protein to form a carbamate bond. This may involve reduction of the mutameric terminus to a primary hydroxyl, optional protection / deprotection of the primary hydroxyl, reaction of the primary hydroxyl with CDI to form a CDI carbamate intermediate and coupling the CDI carbamate intermediate to an amino group on the protein.

[0082] The ratio of polysaccharide to carrier protein for pneumococcal conjugate vaccines is typically in the range of 0.3-3.0 (w / w), but may vary with serotype. The ratio may be determined by independent measurements of the amounts of protein and polysaccharide present, or by methods known in the art for making direct ratio measurements. 1 H NMR spectroscopy or SEC-HPLC-UV / RI coupled with dual monitoring (e.g. refractive index and UV for total material and protein content, respectively) and by SEC-HPLC-MALLS or MALDI-TOF-MS methods, the sugar / protein ratio can be profiled with respect to the conjugate size distribution.

[0083] The polysaccharide-protein conjugates thus obtained can be purified and enriched by a variety of methods. These methods include concentration / diafiltration, column chromatography and depth filtration. The purified polysaccharide-protein conjugates are combined to formulate a mixed carrier, a 21-valent pneumococcal conjugate composition, which can be used as a vaccine.

[0084] The preparation of the vaccine composition can be completed using industry-recognized methods. The vaccine composition is formulated to be compatible with its intended route of administration. Individual pneumococcal capsular polysaccharide-protein conjugates can be formulated with a physiologically acceptable vehicle to prepare the composition. Examples of such vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and dextrose solutions.

[0085] In some embodiments, the mixed carrier, 21-valent pneumococcal conjugate composition further comprises an adjuvant. As used herein, "adjuvant" refers to a substance or vehicle that non-specifically increases the immune response to an antigen. The adjuvant may include a suspension of minerals (alum, aluminum salts, such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, hydroxyaluminum phosphate sulfate, etc.), on which the antigen is adsorbed; or an antigen solution is emulsified in an oil-in-water emulsion in mineral oil (e.g., Freund's incomplete adjuvant), sometimes with the addition of killed mycobacterial contents (Freund's complete adjuvant) to further increase antigenicity. Immunostimulatory oligonucleotides (such as those including a CpG motif) can also be used as adjuvants (e.g., see U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; 6,339,068; 6,406,705; and 6,429,199). Adjuvants also include biological molecules such as lipids and co-stimulatory molecules. Exemplary biological adjuvants include AS04 [9], IL-2, RANTES, GM-CSF, TNF-α, IFN-γ, G-CSF, LFA-3, CD72, B7-1, B7-2, OX-40L and 41BBL.

[0086] In some embodiments, adjuvant is aluminum-based adjuvant.Usually, single 0.5ml vaccine dose is formulated as aluminum-based adjuvant comprising about 0.1mg to 2.5mg.In other embodiments, single 0.5ml vaccine dose is formulated as aluminum-based adjuvant comprising between 0.1mg to 2mg, 0.1mg to 1mg, 0.1mg to 0.5mg, 0.1mg to 0.2mg, 0.125mg to 2.5mg, 0.125mg to 0.5mg, 0.125mg to 0.2mg or 0.125 to 0.25mg.In certain embodiments, single 0.5ml vaccine dose is formulated as aluminum-based adjuvant comprising about 0.125mg to about 0.250mg.In certain embodiments, single 0.5ml vaccine dose is formulated as aluminum-based adjuvant comprising about 0.125mg.In certain embodiments, single 0.5ml vaccine dose is formulated as aluminum-based adjuvant comprising about 0.250mg.

[0087] In a particular embodiment, the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide.

[0088] In a particular embodiment, the adjuvant is aluminum phosphate.

[0089] In some embodiments, the composition is for use as a vaccine against S. pneumoniae infection.

[0090] Characterization of Pneumococcal Capsular Polysaccharide-Protein Carrier Conjugates

[0091] In certain embodiments, the polysaccharide-protein conjugate may have a molecular weight of 100-10,000 kDa. In certain embodiments, the conjugate has a molecular weight of 200-9,000 kDa. In certain embodiments, the conjugate has a molecular weight of 300-8,000 kDa. In certain embodiments, the conjugate has a molecular weight of 400-7,000 kDa. In certain embodiments, the conjugate has a molecular weight of 500-6,000 kDa. In certain embodiments, the conjugate has a molecular weight of 600-5,000 kDa. In certain embodiments, the conjugate has a molecular weight of 500-4,000 kDa molecular weight. Any integer within any one of the above ranges is contemplated as an embodiment of the present disclosure.

[0092] When the molecular weight falls within the above range, the conjugate can be stably formed with high yield. In addition, the proportion of free polysaccharides can be reduced. In addition, excellent immunogenicity can be achieved within the above molecular weight range.

[0093] After purification of the individual polysaccharide-protein conjugates, they are complexed to formulate the immunogenic compositions of the present disclosure.

[0094] The serotype-containing carbohydrate-protein conjugates of the present disclosure can be characterized by the ratio of polysaccharide to protein carrier (amount of polysaccharide / amount of protein carrier, w / w).

[0095] In certain embodiments, the ratio of polysaccharide to protein carrier (w / w) in the polysaccharide-protein carrier conjugate of each serotype is 0.5-2.5, 0.4-2.3, 0.3-2.1, 0.24-2, 0.2-1.8, 0.18-1.6, 0.16-1.4, 0.14-1.2, 0.12-1, or 0.1-1 (e.g., about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, or about 2.5).

[0096] When the ratio of polysaccharide to protein carrier falls within the above range, a conjugate can be stably formed with high yield. In addition, the proportion of free polysaccharide can be reduced. In addition, superior immunogenicity can be achieved within the above range and the conjugate can be stably maintained without interference from other serotypes.

[0097] The conjugates and immunogenic compositions of the present disclosure may include free polysaccharides that are not covalently conjugated to a protein carrier, but are present in the polysaccharide-protein carrier conjugate composition. The free polysaccharide may be non-covalently associated with the polysaccharide-protein carrier conjugate (i.e., non-covalently bound to, adsorbed on, or embedded in or through the polysaccharide-protein carrier conjugate).

[0098] In certain embodiments, the polysaccharide-protein carrier conjugate comprises less than about 60%, about 50%, 45%, 40%, 35%, 30%, 25%, 20% or 15% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype. In certain embodiments, the polysaccharide-protein carrier conjugate of each serotype comprises less than about 60% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype. In certain embodiments, the polysaccharide-protein carrier conjugate of each serotype comprises less than about 50% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype. In certain embodiments, the polysaccharide-protein carrier conjugate of each serotype comprises less than about 40% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype. In certain embodiments, the polysaccharide-protein carrier conjugate of each serotype comprises less than about 30% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype. In certain embodiments, the polysaccharide-protein carrier conjugate of each serotype comprises less than about 25% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype. In certain embodiments, the polysaccharide-protein carrier conjugate of each serotype comprises less than about 20% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype. In certain embodiments, the polysaccharide-protein carrier conjugate of each serotype comprises less than about 15% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype. In certain embodiments, the polysaccharide-protein carrier conjugate of each serotype comprises less than about 10% of free polysaccharide of each serotype based on the total amount of polysaccharide of each serotype.

[0099] The polysaccharide-protein carrier conjugates of each serotype can also be characterized by their molecular size distribution (K d ) for characterization. The relative molecular size distribution of the conjugate can be determined using a size exclusion chromatography medium (CL-4B; cross-linked agarose beads, 4%). The molecular size distribution of the conjugate is analyzed using size exclusion chromatography (SEC) in a gravity feed column. Large molecules excluded from the pores in the medium elute faster than small molecules. The column eluate is collected using a fraction collector. The fractions are tested colorimetrically by sugar assay. Calibration is used to determine Kd Column to establish the fraction that completely excludes molecules (V 0 ; K d = 0) and the fraction representing the maximum retention (V i ; K d =1). The fraction that achieves the specified sample attribute (V e ) through the expression K d =(V e -V 0 ) / (V i -V 0 ) and K d Related.

[0100] In certain embodiments, at least 15% of the polysaccharide-protein carrier conjugates of each serotype may have a K of 0.3 or less in a CL-4B column. d .

[0101] In certain embodiments, at least 20% of the polysaccharide-protein carrier conjugates of each serotype may have a K of 0.3 or less in a CL-4B column. d In certain embodiments, at least 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% of the polysaccharide-protein carrier conjugates of each serotype may have a K of 0.3 or less in a CL-4B column. d In certain embodiments, at least 60% of the polysaccharide-protein carrier conjugates of each serotype may have a K of 0.3 or less in a CL-4B column. d In certain embodiments, at least 50-80% of the polysaccharide-protein carrier conjugates of each serotype may have a K of 0.3 or less in a CL-4B column. d In certain embodiments, at least 65-80% of the polysaccharide-protein carrier conjugates of each serotype may have a K of 0.3 or less in a CL-4B column. d In certain embodiments, at least 15-60% of the sugar-protein conjugates of each serotype may have a K of 0.3 or less in a CL-4B column. d .

[0102] Prevention methods and uses

[0103] In one aspect, the present disclosure provides a vaccine comprising a mixed carrier, a 21-valent pneumococcal conjugate composition, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient comprises at least a buffer such as a succinate buffer, a salt such as sodium chloride, and / or a surfactant such as a polyoxyethylene sorbitan ester (e.g., polysorbate 80). In some embodiments, three or four capsular polysaccharides from a specific serotype as mentioned above are conjugated to tetanus toxoid, and the remaining capsular polysaccharides in 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F are conjugated to CRM. 197 Conjugation (21-valent).

[0104] In one embodiment, capsular polysaccharides from serotypes 1, 5, 15B, and 22F are conjugated to tetanus toxoid, and capsular polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM. 197 Conjugation (21-valent).

[0105] In another embodiment, capsular polysaccharides from serotypes 1, 3, 15B, and 22F are conjugated to tetanus toxoid, and capsular polysaccharides from serotypes 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM. 197 Conjugation (21-valent).

[0106] In another embodiment, capsular polysaccharides from serotypes 3, 5, 15B and 22F are conjugated to tetanus toxoid and capsular polysaccharides from serotypes 1, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F and 33F are conjugated to CRM 197 Conjugation (21-valent).

[0107] In some embodiments, the vaccine elicits a protective immune response in a human subject against disease caused by infection with S. pneumoniae.

[0108] According to another aspect, the disclosure provides a method for preventing pneumococcal infection or disease, the method comprising administering to a human subject a prophylactically effective amount of a mixed vector, a 21-valent pneumococcal conjugate composition, or a vaccine comprising the composition. The mixed vector, 21-valent pneumococcal conjugate composition, or a vaccine comprising the composition can be administered by any route, including, for example, by systemic or mucosal routes, as described in more detail below.

[0109] In certain embodiments, the human subject is an elderly subject and the disease is pneumonia or invasive pneumococcal disease (IPD). In certain embodiments, the elderly subject is at least 50 years old. In other embodiments, the elderly subject is at least 55 years old. In other embodiments, the elderly subject is at least 60 years old.

[0110] In other embodiments, the human subject is an infant and the disease is pneumonia, invasive pneumococcal disease (IPD) or acute otitis media (AOM). In certain embodiments, the infant is 0-2 years old. In other embodiments, the infant is 2 to 15 months.

[0111] In another embodiment, the human subject is 6 weeks to 17 years old and the disease is pneumonia, invasive pneumococcal disease (IPD) or acute otitis media (AOM). In certain embodiments, the human subject is 6 weeks to 5 years old. In other embodiments, the human subject is 5 to 17 years old.

[0112] The amount of conjugate in each vaccine dose or the prophylactically effective amount of the mixed carrier, multivalent pneumococcal conjugate composition can be selected as an amount that induces a prophylactic effect without obvious adverse effects. This amount may vary depending on the pneumococcal serotype. In general, each dose may include about 0.1 μg to about 100 μg of polysaccharide, specifically, about 0.1 to 10 μg, and more specifically, about 1 μg to about 5 μg. The optimal amount of components for a particular vaccine can be determined by standard studies that involve observing appropriate immune responses in subjects. For example, the amount of vaccination for human subjects can be determined by extrapolating animal test results. In addition, the dosage can be determined empirically.

[0113] In some embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition can be a single 0.5 ml dose, which is formulated to contain about 1 μg to about 5 μg of each capsular polysaccharide; about 1 μg to about 30 μg of TT; about 20 μg to about 85 μg of CRM 197; and optionally about 0.1 mg to about 0.5 mg of elemental aluminum adjuvant. In some embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition can be a single 0.5 ml dose, which is formulated to contain about 2 μg to about 2.5 μg of each capsular polysaccharide, except that serotype 6B and optionally serotype 3 are present in an amount of about 4 μg to about 5 μg; about 2 μg to about 25 μg of TT; about 40 μg to about 75 μg of CRM 197 ; and optionally from about 0.1 mg to about 0.25 mg of an elemental aluminum adjuvant.

[0114] In some embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition may be a single 0.5 ml dose formulated to contain about 2.2 μg of each capsular polysaccharide, except for serotype 6B which is present in an amount of about 4.4 μg.

[0115] In some embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition can be a single 0.5 ml dose, which is formulated to contain about 2 μg to about 2.5 μg of each capsular polysaccharide, except that up to six capsular polysaccharides selected from the group consisting of serotypes 1, 3, 4, 5, 6B, 9V, 19A and 19F are each present in an amount of about 4 μg to about 5 μg. In one embodiment, up to six capsular polysaccharides present in an amount of about 4 μg to about 5 μg are selected from the group consisting of serotypes 1, 3, 4, 6B, 9V, 19A and 19F. In other embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition can be a single 0.5 ml dose, which is formulated to contain about 2.2 μg of each capsular polysaccharide, except that up to six capsular polysaccharides selected from the group consisting of serotypes 1, 3, 4, 5, 6B, 9V, 19A and 19F are each present in an amount of about 4.4 μg. In one embodiment, up to six capsular polysaccharides present in an amount of about 4.4 μg are selected from the group consisting of serotypes 1, 3, 4, 6B, 9V, 19A and 19F.

[0116] In some embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition can be a single 0.5 ml dose formulated to contain about 2 μg to about 2.5 μg of capsular polysaccharides of serotypes 4, 5, 6A, 7F, 8, 9V, 9N, 10A, 11A, 12F, 14, 15B, 18C, 22F, 23F and 33F, and about 4 μg to about 5 μg of capsular polysaccharides of serotypes 1, 3, 6B, 19A and 19F.

[0117] In some embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition can be a single 0.5 ml dose formulated to contain about 2 μg to about 2.5 μg of capsular polysaccharides of serotypes 1, 5, 6A, 7F, 8, 9N, 10A, 11A, 12F, 14, 15B, 18C, 22F, 23F and 33F, and about 4 μg to about 5 μg of capsular polysaccharides of serotypes 3, 4, 6B, 9V, 19A and 19F.

[0118] In certain embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition can be a single 0.5 ml dose formulated to contain about 2-2.5 μg of capsular polysaccharides of serotypes 1, 4, 5, 6A, 7F, 8, 9V, 9N, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, and about 4 to about 5 μg of capsular polysaccharides of serotypes 3 and 6B.

[0119] In some embodiments, the vaccine or mixed carrier, 21-valent pneumococcal conjugate composition can be a single 0.5 ml dose formulated to contain about 2 to about 2.5 μg of capsular polysaccharides of serotypes 1, 4, 5, 6A, 7F, 8, 9V, 9N, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, and about 4 to about 5 μg of capsular polysaccharide of serotype 6B and about 8 to about 9 μg of capsular polysaccharide of serotype 3, and more preferably about 8.8 μg of capsular polysaccharide of serotype 3.

[0120] In certain embodiments, the mixed carrier, the 21-valent pneumococcal conjugate composition, or a vaccine comprising the composition further comprises sodium chloride and sodium succinate buffer as excipients.

[0121] In some embodiments, a mixed carrier, 21-valent pneumococcal conjugate composition can be formulated as a liquid formulation in which each of the pneumococcal capsular polysaccharides of serotypes 1, 5, 15B, and 22F is conjugated to TT and the capsular polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM. 197 Conjugated (21-valent). Each 0.5 mL dose can be formulated as a liquid containing: about 2.2 μg of each capsular polysaccharide, except for serotype 6B, which is about 4.4 μg; about 2 μg to about 25 μg of TT carrier protein (only for serotypes 1, 5, 15B and 22F) and about 40 μg to about 75 μg of CRM 197carrier protein; about 0.125 to 0.250 mg of elemental aluminum (about 0.5 to 1.2 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients.

[0122] In some embodiments, a mixed carrier, 21-valent pneumococcal conjugate composition can be formulated as a liquid formulation in which each of the pneumococcal capsular polysaccharides of serotypes 3, 5, 15B, and 22F is conjugated to TT and the capsular polysaccharides from serotypes 1, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM. 197 Conjugation (21 valent). In one embodiment, each 0.5 mL dose can be formulated as a liquid containing the following: about 2.2 μg of each capsular polysaccharide, except for serotype 6B, which is about 4.4 μg; about 2 μg to about 25 μg of TT carrier protein (only for serotypes 3, 5, 15B and 22F) and about 40 μg to about 70 μg of CRM 197 carrier protein; about 0.125 mg to about 0.250 mg of elemental aluminum (about 0.5 to 1.2 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients. In another embodiment, each 0.5 mL dose can be formulated as a liquid containing the following: about 2.2 μg of each capsular polysaccharide, except for up to six capsular polysaccharides selected from the group consisting of serotypes 1, 3, 4, 5, 6B, 9V, 19A and 19F, which is about 4.4 μg; about 2 μg to about 25 μg of TT carrier protein (only for serotypes 3, 5, 15B and 22F) and about 40 μg to about 70 μg of CRM 197 carrier protein; about 0.125 mg to about 0.250 mg of elemental aluminum (about 0.5 to 1.2 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients. In one embodiment, about 4.4 μg of up to six capsular polysaccharides are selected from the group consisting of serotypes 1, 3, 4, 6B, 9V, 19A and 19F. In another embodiment, each 0.5 mL dose can be formulated as a liquid containing the following: about 2.2 μg of each capsular polysaccharide, except for serotypes 1, 3, 6B, 19A and 19F, which is about 4.4 μg; about 2 μg to about 25 μg of TT carrier protein (only for serotypes 3, 5, 15B and 22F) and about 40 μg to about 70 μg of CRM 197 carrier protein; about 0.125 mg to about 0.250 mg of elemental aluminum (about 0.5 to 1.2 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients.

[0123] In some embodiments, a mixed carrier, 21-valent pneumococcal conjugate composition can be formulated as a liquid formulation in which each of the pneumococcal capsular polysaccharides of serotypes 1, 3, 15B, and 22F is conjugated to TT and the capsular polysaccharides from serotypes 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM. 197 Conjugation (21 valent). In one embodiment, each 0.5 mL dose can be formulated as a liquid containing the following: about 2.2 μg of each capsular polysaccharide, except for serotype 6B, which is about 4.4 μg; about 2 μg to about 25 μg of TT carrier protein (only for serotypes 1, 3, 15B and 22F) and about 40 μg to about 75 μg of CRM 197 carrier protein; about 0.125 mg to about 0.250 mg of elemental aluminum (about 0.5 to 1.2 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients.

[0124] In some embodiments, the liquid formulation can be filled into a single-dose syringe without a preservative.After shaking, the liquid formulation becomes a homogenous, white suspension vaccine ready for intramuscular administration.

[0125] The mixed carrier, 21-valent pneumococcal conjugate composition can be administered as a single injection or as part of an immunization series. For example, the mixed carrier, 21-valent pneumococcal conjugate composition can be administered 2, 3, 4 or more times at appropriately spaced intervals, such as 1, 2, 3, 4, 5 or 6 months, or a combination thereof. In some embodiments, the mixed carrier, 21-valent pneumococcal conjugate composition is administered to an infant 4 times within the first 15 months of birth, including, for example, at about 2, 3, 4 and 12-15 months of age; at about 3, 4, 5 and 12-15 months of age; or at about 2, 4, 6 and 12 to 15 months of age. This first dose can be administered as early as 6 weeks of age. In another embodiment, the mixed carrier, 21-valent pneumococcal conjugate composition is administered to an infant 3 times within the first 15 months of birth, including, for example, at about 2, 4 and 11-12 months.

[0126] The mixed carrier, multivalent pneumococcal conjugate composition may also include one or more proteins from S. pneumoniae. Examples of S. pneumoniae proteins suitable for inclusion include those identified in International Patent Application WO02 / 083855, and those described in International Patent Application WO02 / 053761.

[0127] The mixed carrier, 21-valent pneumococcal conjugate composition can be administered to a subject by one or more routes of administration known to those of ordinary skill in the art, such as parenteral, transdermal or transmucosal, intranasal, intramuscular, intraperitoneal, intradermal, intravenous or subcutaneous and formulated accordingly. The mixed carrier, 21-valent pneumococcal conjugate composition can be formulated to be compatible with its intended route of administration.

[0128] In some embodiments, a mixed carrier, a 21-valent pneumococcal conjugate composition in the form of a liquid preparation can be administered by intramuscular, intraperitoneal, subcutaneous, intravenous, intraarterial, or percutaneous injection or respiratory mucosal injection. Mixed carriers, 21-valent pneumococcal conjugate compositions can be prepared in liquid form or lyophilized form. In some embodiments, injectable compositions are prepared in conventional forms, such as liquid solutions or suspensions, solid forms before injection of solutions or suspensions suitable for liquids, or emulsions. In some embodiments, injection solutions or suspensions are prepared from sterile powders or particles. For the preparation and manufacture of pharmaceutical preparations for use by these routes, generally things that need to be considered can be, for example, found in Remington's Pharmaceutical Sciences, 19th edition, Mack Publishing Co., Easton, PA, 1995; it is incorporated herein by reference. At present, oral or nasal spray or aerosol (aerosol) routes (e.g., by inhalation) are most commonly used to deliver therapeutic agents directly to the lungs and respiratory system. In some embodiments, mixed carrier, 21-valent pneumococcal conjugate composition are applied using a device for delivering a metered dose of the composition. Suitable devices for delivering intradermal pharmaceutical compositions as described herein include short needle devices, such as those described in U.S. Patent No. 4,886,499, U.S. Patent No. 5,190,521, U.S. Patent No. 5,328,483, U.S. Patent No. 5,527,288, U.S. Patent No. 4,270,537, U.S. Patent No. 5,015,235, U.S. Patent No. 5,141,496, U.S. Patent No. 5,417,662 (all of which are incorporated herein by reference). Intradermal compositions can also be applied by limiting the device for effectively piercing the length of the needle into the skin, such as those described in WO1999 / 34850 incorporated herein by reference, and its functional equivalent. Also suitable is a jet injection device, which delivers liquid vaccines to the dermis by a liquid jet injector or by piercing the stratum corneum and producing a needle of a spray that reaches the dermis.Jet injection devices are described, for example, in U.S. Pat. No. 5,480,381, U.S. Pat. No. 5,599,302, U.S. Pat. No. 5,334,144, U.S. Pat. No. 5,993,412, U.S. Pat. No. 5,649,912, U.S. Pat. No. 5,569,189, U.S. Pat. No. 5,704,911, U.S. Pat. No. 5,383,851, U.S. Pat. No. 5,893,397, U.S. Pat. No. 5,466,220, U.S. Pat. No. 5,33 9,163, U.S. Patent No. 5,312,335, U.S. Patent No. 5,503,627, U.S. Patent No. 5,064,413, U.S. Patent No. 5,520,639, U.S. Patent No. 4,596,556, U.S. Patent No. 4,790,824, U.S. Patent No. 4,941,880, U.S. Patent No. 4,940,460, WO1997 / 37705 and WO1997 / 13537 (all of which are incorporated herein by reference). Also suitable is a ballistic powder / particle delivery device that uses compressed gas to accelerate the vaccine in powder form through the outer layer of the skin to the dermis. In addition, the classical Mantoux intradermal administration method can use a conventional syringe.

[0129] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, oils such as olive oil, and injectable organic esters such as ethyl oleate. Examples of oils include vegetable or animal oils, peanut oil, soybean oil, olive oil, sunflower oil, liver oil, synthetic oils such as aquatic oils, and lipids obtained from milk or eggs. Aqueous carriers include water, alcohol / aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's (Ringer's) dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient supplements, electrolyte supplements (such as those based on Ringer's dextrose) and the like. Preservatives and other additives may also be present, for example, antimicrobial agents, antioxidants, chelating agents and inert gases and the like.

[0130] Mixed carrier, 21-valent pneumococcal conjugate composition can be formulated in the form of unit dose vials, multi-dose vials or pre-filled syringes. Pharmaceutically acceptable carriers for liquid preparations include aqueous or non-aqueous solvents, suspensions, emulsions or oils. The composition can be isotonic, hypertonic or hypotonic. However, it is desirable that the composition for infusion or injection is substantially isotonic. Therefore, isotonicity or hypertonicity can be beneficial to the storage of the composition. When the composition is hypertonic, the composition can be diluted to isotonicity before administration. Isotonicity agents can be ionic isotonicity agents such as salts, or non-ionic isotonicity agents such as carbohydrates. Ionic isotonicity agents include but are not limited to sodium chloride, calcium chloride, potassium chloride and magnesium chloride. Non-ionic isotonicity agents include but are not limited to sorbitol and glycerol. Preferably, at least one pharmaceutically acceptable buffer is included. For example, when the composition is an infusion or injection, the composition is preferably formulated in a buffer having a buffering capacity of pH 4 to pH 10 (such as pH 5 to pH 9 or pH 6 to pH 8). The buffer can be selected from those applicable to the United States Pharmacopeia (USP). For example, the buffer can be selected from the group consisting of: monoacids such as acetic acid, benzoic acid, gluconic acid, glyceric acid and lactic acid; diacids such as aconitic acid, adipic acid, ascorbic acid, carbonic acid, glutamic acid, malic acid, succinic acid and tartaric acid; polyacids such as citric acid and phosphoric acid; and bases such as ammonia, diethanolamine, glycine, triethanolamine and TRIS.

[0131] The mixed carrier, 21-valent pneumococcal conjugate composition may contain a surfactant. Examples of surfactants include, but are not limited to, polyoxyethylene sorbitan esters (commonly known as Tweens), in particular, polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), butylene oxide (BO) (such as DOWFAX); octoxynols with varying repeats of ethoxy (oxy-1,2-ethanediyl) groups, in particular, octoxynols-9 (Triton-100); ethylphenoxypolyethoxyethanol (IGEPAL CA-630 / NP-40); phospholipids such as lecithin; nonylphenol ethoxylates such as the TERGITOL NP series; polyoxyethylene fatty ethers derived from lauryl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol (Brij surfactants), in particular, triethylene glycol monolauryl ether (Brij 30); sorbitan ethers known as SPANs. ether), in particular, sorbitan trioleate (Span 85) and sorbitan monolaurate.

[0132] Mixtures of surfactants may be used, such as Tween 80 / Span 85. Combinations of polyoxyethylene sorbitan esters such as Tween 80 and octoxynol such as Triton X-100 are also suitable. Combinations of Laureth 9 and Tween and / or octoxynol are also advantageous. Preferably, the amount of polyoxyethylene sorbitan ester (such as Tween 80) included can be 0.01% to 1% (w / v), 0.01% to 0.1% (w / v), 0.01% to 0.05% (w / v) or about 0.02%; the amount of octylphenoxypolyoxyethanol or nonylphenol polyoxyethylene ether (such as TritonX-100) included can be 0.001% to 0.1% (w / v), especially 0.005% to 0.02%; and the amount of polyoxyethylene ether (such as laureth 9) included can be 0.1% to 20% (w / v), possibly 0.1% to 10%, especially 0.1% to 1% or about 0.5%.

[0133] In some embodiments, the mixed carrier, 21-valent pneumococcal conjugate composition can be delivered by a release control system. For example, intravenous infusion, transdermal patch, liposome or other routes of administration can be used. In one aspect, macromolecules such as microspheres or implants can be used.

[0134] The above disclosure generally describes the present invention. A more comprehensive understanding can be obtained with reference to the following specific examples. These examples are only for illustrative purposes and are not intended to limit the scope of the present invention.

[0135] Example

[0136] Example 1. Preparation of Streptococcus pneumoniae capsular polysaccharide

[0137] The cultivation of S. pneumoniae and the purification of capsular polysaccharides are performed as known to those skilled in the art. S. pneumoniae serotypes are obtained from the American Type Culture Collection (ATCC) (Serotype 1: ATCC No. 6301; Serotype 3: ATCC No. 6303; Serotype 4: ATCC No. 6304; Serotype 5: ATCC No. 6305; Serotype 6A: ATCC No. 6306; Serotype 6B: ATCC No. 6326; Serotype 7F: ATCC No. 10351; Serotype 9N: ATCC No. 6309; Serotype 9V: ATCC No. 10368; Serotype 14: ATCC No. 6314; Serotype 18C: ATCC No. 10356; Serotype 19A: ATCC No. 10357; Serotype 19F: ATCC No. 6319; Serotype 23F: ATCC No. 6323). Serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F use internal strains, but any publicly available strain may be used. S. pneumoniae is characterized by capsule and motility, Gram-positive, lancet-shaped diplococci, and alpha-hemolytic in blood agar medium. Serotypes are identified by Quelling tests using specific antisera (U.S. Pat. No. 5,847,112).

[0138] Preparation of cell banks

[0139] Several generations of seed stocks are produced in order to expand the strains and remove animal-derived components (F1, F2 and F3 generations). Two additional generations of seed stocks are produced. The additional first generation is cultured from the F3 vial, and the subsequent generation is cultured from the additional first generation vial. The seed vials are frozen (below -70°C) using synthetic glycerol as a cryopreservative. For cell bank preparation, all cultures are grown in soy-based medium. Prior to freezing, the cells are concentrated by centrifugation, the spent medium is removed, and the cell pellet is resuspended in fresh medium containing a cryopreservative, such as synthetic glycerol.

[0140] Cultivation and harvesting

[0141] The culture from the working cell bank is inoculated into a seed bottle containing a soy-based medium and cultured. After reaching the target optical density (absorbance), the seed bottle is used to inoculate a fermenter containing a soy-based medium. The culture is terminated when the optical density value begins to remain fixed. After terminating the culture, sodium deoxycholate is added to the culture to lyse the cells. The resulting fermenter contents are cooled and protein precipitation is induced. Next, the mixture is centrifuged to remove the precipitated protein and cell debris.

[0142] purification

[0143] The solution obtained by centrifugation is filtered through a depth filter to remove protein and cell debris that have not yet precipitated in the centrifugation. The filtrate is concentrated on a 100kDa MW membrane and the concentrate is diafiltered with 10 times the volume of 25mM sodium phosphate buffer (pH 7.2) to obtain a sample. The sample is filtered to collect the suspension, and polysaccharides are precipitated and filtered by the suspension. The filtrate is concentrated on a 30kDa membrane, and the concentrate is diafiltered with about 10 times the volume of triple distilled water. After diafiltration, the remaining solution is filtered through a 0.2 μm filter. The filtrate is subjected to control tests (total amount of appearance, remaining protein, remaining nucleic acid, endotoxin, molecular weight and polysaccharides) during the process. The concentrate is sterile filtered and stored at -20°C.

[0144] Example 2. Preparation of a conjugate of Streptococcus pneumoniae capsular polysaccharide and a carrier protein

[0145] Polysaccharides of different serotypes are activated in different ways and then bind to the carrier protein CRM 197 Specifically, by conjugating each of the capsular polysaccharides of all serotypes (except 15B and 22F) with CRM 197 Conjugates are prepared by conjugating each of the capsular polysaccharides of serotypes 1, 3, 5, 15B and 22F with TT. The activation process may include reducing the size of each capsular polysaccharide to a target molecular weight, chemical activation, and buffer exchange by ultrafiltration depending on the size of the native serotype. The conjugates are purified using ultrafiltration and finally filtered through a 0.2 μm filter. Process parameters such as pH, temperature, concentration, and time are as follows.

[0146] (1) Activation process

[0147] Step 1: Hydrolysis

[0148] Reductive amination is a known method for conjugating polymers, in which the primary amine (-NH 2 ) group to form an amide bond with the aldehyde of the sugar. Aldehyde groups are added to pneumococcal capsular polysaccharides to facilitate conjugation with carrier proteins. The vicinal diol structure of the monosaccharide can be prepared by sodium periodate (NaIO 4 ) were oxidized to form aldehyde groups. Capsular polysaccharides from serotypes 1, 3, 4, 6A, 8, 11A, 12F, 14, 15B, 18C, 22F and 33F were pretreated as follows.

[0149] In the case of serotype 1, sodium hydroxide (at a final base concentration of 0.05 M) is added to the solution of capsular polysaccharide, and the solution is incubated at 50±2° C. The solution is then cooled to a temperature in the range of about 21° C. to about 25° C., and hydrochloric acid is added thereto to a final pH of 6.0±0.1, thereby stopping the hydrolysis.

[0150] In the case of serotypes 3, 8, 11A and 15B, hydrochloric acid (at a final acid concentration of 0.01 M) is added to the solution of capsular polysaccharide, and the solution is incubated at 60±2° C. The solution is then cooled to a temperature in the range of about 21° C. to about 25° C., and 0.1 M sodium phosphate is added thereto to a final pH of 6.0±0.1, thereby stopping the hydrolysis.

[0151] In the case of serotype 4, hydrochloric acid (at a final acid concentration of 0.1 M) is added to the solution of capsular polysaccharide, and the solution is incubated at 45±2° C. The solution is then cooled to a temperature in the range of about 21° C. to about 25° C., and 1 M sodium phosphate is added thereto to a final pH of 6.0±0.1, thereby stopping the hydrolysis.

[0152] In the case of serotype 6A, glacial acetic acid (at a final acid concentration of 0.1 M) is added to the solution of capsular polysaccharide, and the solution is incubated at 60° C.±2° C. The solution is then cooled to a temperature in the range of about 21° C. to about 25° C., and 1 M sodium hydroxide is added thereto to a final pH of 6.0±0.1, thereby stopping the hydrolysis.

[0153] In the case of serotype 12F, hydrochloric acid (at a final acid concentration of 0.01 M) is added to the solution of capsular polysaccharide, and the solution is incubated at 70° C.±2° C. The solution is then cooled to a temperature in the range of about 21° C. to about 25° C., and 0.1 M sodium phosphate is added thereto to a final pH of 6.0±0.1, thereby stopping the hydrolysis.

[0154] In the case of serotypes 14 and 18C, glacial acetic acid (at a final acid concentration of 0.2 M) is added to the solution of capsular polysaccharide, and the solution is incubated at 94±2° C. The solution is then cooled to a temperature in the range of about 21° C. to about 25° C., and 1 M sodium phosphate is added thereto so that the final pH of the solution is 6.0±0.1, thereby stopping the hydrolysis.

[0155] In the case of serotypes 22F and 33F, hydrochloric acid (at a final acid concentration of 0.01 M) is added to the solution of capsular polysaccharide, and the solution is incubated at 60° C.±2° C. The solution is then cooled to a temperature in the range of about 21° C. to about 25° C., and 0.1 M sodium phosphate is added thereto to a final pH of 6.0±0.1, thereby stopping the hydrolysis.

[0156] Each of the obtained capsular polysaccharides was diluted with water for injection (WFI), sodium acetate, and sodium phosphate to a final concentration between about 1.0 mg / mL and about 2.0 mg / mL.

[0157] Step 2: Periodate reaction

[0158] The molar equivalent of sodium periodate used for activation of each pneumococcal saccharide was determined based on the repeat unit molar mass. All serotypes were subjected to oxidation reactions at 21°C to 25°C for 16 to 20 hours with adequate mixing, except for serotypes 1, 7F and 19F, which were 10°C or lower. In order to help maintain consistent and stable conjugate production, a range of oxidation degree (Do) levels was set for each serotype during the conjugation process. Tables 1 and 2 show the preferred setting ranges for the Do levels for each serotype.

[0159] Table 1. CRM to be used 197 Do range for all serotypes conjugated

[0160] Serotype Do Range Serotype Do Range Serotype 1 4 to 10 Serotype 10A 1 to 12 Serotype 3 2 to 8 Serotype 11A 1 to 15 Serotype 4 1 to 5 Serotype 12F 1 to 9 Serotype 6A 5 to 15 Serotype 14 6 to 13 Serotype 6B 7 to 13 Serotype 18C 6 to 14 Serotype 7F 2 to 8 Serotype 19A 7 to 13 Serotype 8 1 to 17 Serotype 19F 6 to 12 Serotype 9N 5 to 10 Serotype 23F 6 to 14 Serotype 9V 4 to 9 Serotype 33F 1 to 15

[0161] Table 2. Do ranges for serotypes 1, 3, 5, 15B and 22F to be conjugated to TT

[0162]

[0163] Step 3: Ultrafiltration

[0164] The oxidized sugars were concentrated and diafiltered with WFI on a 100 kDa MWCO ultrafilter (30 kDa ultrafilter for serotype 1 and 5 kDa ultrafilter for serotype 18C). Diafiltration for serotype 1 was performed using 0.9% sodium chloride solution, 0.01 M sodium acetate buffer (pH 4.5) for serotypes 7F and 23F, and 0.01 M sodium phosphate buffer (pH 6.0) for serotype 19F. The permeate was discarded and the retentate was filtered through a 0.2 μm filter.

[0165] Step 4: Freeze Drying

[0166] For capsular polysaccharides of serotypes 3, 4, 5, 8, 9N, 9V, 10A, 14 and 33F to be conjugated with carrier proteins by using aqueous solvents, mixed solutions of polysaccharides and carrier proteins were prepared without adding more sucrose, freeze-dried, and then stored at -25°C ± 5°C.

[0167] For the capsular polysaccharides of serotypes 1 and 18C to be conjugated to carrier proteins by using aqueous solvents, the polysaccharides and carrier proteins were prepared independently without adding more sucrose, freeze-dried, and then stored at -25°C ± 5°C.

[0168] For the capsular polysaccharides of serotypes 6A, 6B, 7F, 15B-TT, 19A, 19F, 22F-TT and 23F to be conjugated to carrier proteins by using DMSO solvent, a predetermined amount of sucrose to achieve a final sucrose concentration of 5% ± 3% (w / v) was added to the activated saccharide, and the samples were prepared independently, freeze-dried, and then stored at -25°C ± 5°C.

[0169] For capsular polysaccharide of serotype 11A, a predetermined amount of sucrose to achieve a final sucrose concentration of 20% ± 5% (w / v) was added to the activated saccharide, and the polysaccharide and carrier protein were prepared independently, freeze-dried, and then stored at -25°C ± 5°C.

[0170] For capsular polysaccharide of serotype 12F, a predetermined amount of sucrose to achieve a final sucrose concentration of 10% ± 5% (w / v) was added to the activated saccharide, and the polysaccharide and carrier protein were prepared independently, freeze-dried, and then stored at -25°C ± 5°C.

[0171] (2) Conjugation process

[0172] Aqueous conjugation was performed for serotypes 1, 3, 4, 5, 8, 9N, 9V, 10A, 14, 18C and 33F, and DMSO conjugation was performed for serotypes 6A, 6B, 7F, 11A, 12F, 15B-TT, 19A, 19F, 22F-TT and 23F. Each capsular polysaccharide was conjugated to the carrier protein at a ratio of 0.2 to 2:1.

[0173] Step 1: Dissolve

[0174] Aqueous conjugation

[0175] For serotypes 1, 3, 4, 5, 8, 9N, 9V, 10A, 14, 18C and 33F, freeze-dried samples were thawed and equilibrated at room temperature. Freeze-dried samples were reconstituted to reaction concentrations at 23 ± 2 °C by using sodium phosphate buffer solution at the ratio set for each serotype.

[0176] Dimethyl sulfoxide (DMSO) conjugation

[0177] For serotypes 6A, 6B, 7F, 11A, 12F, 15B-TT, 19A, 19F, 22F-TT, and 23F, freeze-dried samples were thawed at room temperature, equilibrated, and reconstituted in DMSO.

[0178] Step 2: Conjugation reaction

[0179] Aqueous conjugation

[0180] For serotypes 3-TT, 4, 5-TT, 8, 9N, 9V, 10A, 14, 18C, and 33F, the conjugation reaction was initiated by adding sodium cyanoborohydride solution (100 mg / mL) to 1.0 to 1.4 moles of sodium cyanoborohydride per mole of sugar. However, for serotypes 1, 1-TT, and 3, the reaction was initiated by adding sodium cyanoborohydride solution to 0.5 moles of sodium cyanoborohydride per mole of sugar.

[0181] The reaction mixture is incubated at 23°C to 37°C for 44 to 106 hours. The reaction temperature and time are adjusted according to the serotype. The temperature is then reduced to 23°C ± 2°C and sodium chloride 0.9% is added to the reactor. Sodium borohydride solution (100 mg / mL) is added to achieve 1.8 to 2.2 molar equivalents of sodium borohydride per mole of sugar. The mixture is incubated at 23°C ± 2°C for 3 to 6 hours. This procedure reduces any unreacted aldehyde present on the sugar. Next, the mixture is diluted with sodium chloride 0.9% and the diluted conjugate mixture is filtered with a 0.8 or 0.45 μm prefilter.

[0182] DMSO conjugation

[0183] For capsular polysaccharides of serotypes 6A, 6B, 7F, 11A, 12F, 15B-TT, 19A, 19F, 22F-TT and 23F, the conjugation reaction was initiated by adding sodium cyanoborohydride solution (100 mg / mL) to a ratio of 0.8 to 1.2 molar equivalents of sodium cyanoborohydride per mole of activated sugar. WFI was added to the reaction mixture to a target concentration of 1% (v / v), and the mixture was incubated at 23±2°C for 12 to 26 hours. 100 mg / mL of sodium borohydride solution (usually 1.8 to 2.2 molar equivalents of sodium borohydride per mole of activated sugar) and WFI (target 5% v / v) were added to the reaction and the mixture was incubated at 23±2°C for 3 to 6 hours. This procedure reduces any unreacted aldehydes present on the sugar. Next, the reaction mixture was diluted with sodium chloride 0.9%, and the diluted conjugate mixture was filtered with a 0.8 or 0.45 μm prefilter.

[0184] Step 3: Ultrafiltration

[0185] The diluted conjugate mixture was concentrated and diafiltered on a 100 kDa MWCO ultrafiltration filter or a 300 kDa MWCO ultrafiltration filter with a minimum of 15 volumes of 0.9% sodium chloride or buffer. In addition, the composition and pH of the buffer used in this process varied depending on each serotype.

[0186] Step 4: Sterile Filtration

[0187] The retentate after ultrafiltration was sterile filtered (0.2 μm) and the filtered conjugate was subjected to in-process controls (appearance, free protein, free sugar, molecular size distribution, sterility, sugar content, protein content, pH, endotoxin, residual cyanide, residual DMSO, sugar identification, TT identification and CRM 197 Identification). The final concentrate was refrigerated and stored at 2°C to 8°C.

[0188] Example 3. Formulation of a multivalent pneumococcal conjugate vaccine

[0189] The desired volume of the final bulk concentrate obtained in Example 2 is calculated based on the batch volume and bulk sugar concentration. After 0.85% sodium chloride (normal saline), polysorbate 80 and succinate buffer are added to a pre-labeled formulation container, the bulk concentrate is added. The formulation is then fully mixed and sterile filtered through a 0.2 μm membrane. The formulated bulk is gently mixed during and after the addition of bulk aluminum phosphate. Check pH and adjust pH when necessary. The formulated bulk product is stored at 2 to 8 ° C. The following non-restrictive multivalent pneumococcal conjugate vaccine formulations are prepared and named PCV21 (1 / 5 / 15B / 22F)-TT and PCV21 (3 / 5 / 15B / 22F)-TT:

[0190] By conjugating each polysaccharide of serotypes 1, 5, 15B and 22F to TT and each polysaccharide of serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F and 33F to CRM 197 conjugating to prepare PCV21(1 / 5 / 15B / 22F)-TT comprising a polysaccharide conjugate; and

[0191] By conjugating each polysaccharide of serotypes 3, 5, 15B and 22F to TT and each polysaccharide of serotypes 1, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F and 33F to CRM 197 PCV21(3 / 5 / 15B / 22F)-TT comprising a polysaccharide conjugate was prepared by conjugation.

[0192] The total dose of 0.5 mL of PCV21 (1 / 5 / 15B / 22F)-TT composition includes 2.2 μg of each polysaccharide, except for 4.4 μg of serotype 6B; 2 μg to 25 μg of TT (for serotypes 1, 5, 15B and 22F) and 40 μg to 75 μg of CRM 197, 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; 4.25 mg of sodium chloride; about 295 μg of succinate buffer; and about 100 μg of polysorbate 80, for a total of 0.5 ml dose.

[0193] The PCV21 (3 / 5 / 15B / 22F)-TT composition for a total dose of 0.5 mL includes 2.2 μg of each polysaccharide, except for serotypes 1, 3, 6B, 19A and 19F, which is 4.4 μg; 2 μg to 25 μg of TT (for serotypes 3, 5, 15B and 22F), 0.250 mg of elemental aluminum (1.13 mg aluminum phosphate), and the other components and their contents are exactly the same as those of PCV21 (1 / 5 / 15B / 22F)-TT.

[0194] Example 4. Immunogenicity of multivalent pneumococcal conjugate vaccines

[0195] The mixed carrier, multivalent pneumococcal vaccines, PCV21 (1 / 5 / 15B / 22F)-TT and PCV21 (3 / 5 / 15B / 22F)-TT prepared in Example 3 were tested for their ability to induce an immune response in rabbits. Immunogenicity was assessed by antigen-specific ELISA for serum IgG concentrations and opsonophagocytic assay (OPA) for antibody functionality. New Zealand white rabbits were immunized intramuscularly at weeks 0 and 2 with a dose of each polysaccharide 5% higher than the planned human clinical dose (2.31 μg of each polysaccharide, except 6B at 4.62 μg) in the formulation or at the human dose (2.2 ug of each polysaccharide, except 6B at 4.4 μg). Serum was sampled every 2 weeks after immunization. Both concentrations showed the same results.

[0196] 4-1.PCV21(3 / 5 / 15B / 22F)-TT

[0197] Serotype-specific IgG concentration measurement

[0198] Capsular polysaccharides (PnPs) of each serotype were plated on 96-well plates at 0.5 μg / well to 1 μg / well. Equal amounts of serum were sampled from each subject and mixed by group. Antibody dilution buffer containing Tween 20 and pneumococcal cell wall polysaccharides (CWPS) (5ug / mL) obtained from Statens Serum Institut was used to dilute the serum pool by 2.5 times, and then reacted at room temperature for 30 minutes. The plate was washed 5 times with washing buffer, then pre-absorbed and diluted serum 50uL was added to the plated well plate, and then incubated at room temperature for 2 hours to 18 hours. The well plate was washed in the same manner, and then goat anti-rabbit IgG-alkaline phosphatase conjugate was added to each well, and then incubated at room temperature for 2 hours. The plate was washed as described above and 1mg / mL p-nitroaniline buffer as a substrate was added to each well, and then reacted at room temperature for 2 hours. The reaction was quenched by adding 50uL of 3M NaOH and the absorbance at 405nm and 690nm was measured. A commercially available 13-valent vaccine (Prevnar 13) was subjected to the same procedure as a comparative example. The results are shown in Table 3.

[0199] Table 3. IgG concentrations (U / mL) of 21 serotypes 2 weeks after secondary immunization

[0200]

[0201]

[0202] Capsular polysaccharide of serotypes 3 and 5 and CRM 197 When it was conjugated with TT, the serotype-specific IgG concentration was significantly increased compared to that obtained when conjugated with TT. Rabbits immunized with PCV21 (3 / 5 / 15B / 22F)-TT also showed a significant increase in IgG concentrations to eight additional serotypes (i.e., 8, 9N, 10A, 11A, 12F, 15B, 22F, and 33F) not present in Prevenar 13. In particular, serotype 9N had a greater than 50-fold increase in serum-specific IgG concentration compared to Prevenar 13.

[0203] Functional Immunogenicity Assay (MOPA)

[0204] Antibody function was assessed by testing sera in the MOPA assay. Streptococcus pneumoniae MOPA strains stored at -70°C or lower were diluted to the corresponding final dilution factor so that the concentration of each strain was about 50,000 CFU / mL. Equal amounts of serum were sampled from each subject, mixed by group and serially diluted 2-fold so that 20 μl of serum remained in a U-bottom plate. After diluting the sample, 10 μl of strains prepared for each serotype were mixed with the diluted sample, and the mixture was reacted at room temperature for 30 minutes to allow the Streptococcus pneumoniae and antibodies to be fully mixed. A mixture of pre-differentiated HL-60 cells and complement was added and incubated at CO 2 Incubator (37°C) for 45 minutes. Lower the temperature to stop phagocytosis and apply 10uL of the reaction solution to an agar plate that has been dried for 30 to 60 minutes in advance, and then allow it to be absorbed on the plate for 20 minutes until dry. Add 25mg / mL TTC stock solution to the prepared overlay agar, and add appropriate antibodies for the corresponding strains thereto. Mix the mixture thoroughly, then add about 25mL of the mixture to the plate and harden for about 30 minutes. Place the fully hardened plate in CO 2 The cells were incubated in an incubator (37°C) for 12 to 18 hours and then colonies were counted. The MOPA titer was expressed as the dilution rate at which 50% lethality was observed. A commercially available 13-valent vaccine (Prevnar 13) was subjected to the same procedure as a comparative example. The results are shown in Table 4.

[0205] Table 4. MOPA titers of 21 serotypes 2 weeks after secondary immunization

[0206] Serotype Prevnar 13 PCV21(3 / 5 / 15B / 22F)-TT 1 94 80 3 829 3772 4 2428 2370 5 1169 1972 6A 4925 3094 6B 5693 3927 7F 2731 2386 8 Not tested 669 9N Not tested 2339 9V 271 175 10A Not tested 805 11A Not tested 2040 12F Not tested 894 14 1917 1874 15B Not tested 311 18C 5347 3758 19A 5760 888 19F 2059 710 22F Not tested 1286 23F 1975 1868 33F Not tested 1011

[0207] With serotypes 3 and 5 and CRM 197 Rabbits immunized with PCV21(3 / 5 / 15B / 22F)-TT also showed a significant increase in functional MOPA titers to each of the eight additional serotypes not present in Prevnar 13 (i.e., 8, 9N, 10A, 11A, 12F, 15B, 22F, and 33F).

[0208] 4-2. PCV21(1 / 5 / 15B / 22F)-TT

[0209] Serotype-specific IgG concentrations and functional immunogenicity titers were measured in the same manner as in 4-1, and the results of two separate experiments are shown below.

[0210] Serotype-specific IgG concentration measurement

[0211] Table 5. IgG concentrations (U / mL) of 21 serotypes 2 weeks after secondary immunization

[0212]

[0213] Capsular polysaccharide of serotypes 1 and 5 and CRM 197 When it was conjugated with TT, the serotype-specific IgG concentration was significantly increased compared to that obtained when it was conjugated with TT. Rabbits immunized with PCV21 (1 / 5 / 15B / 22F)-TT also showed a significant increase in IgG concentrations to eight additional serotypes not present in Prevnar 13 (i.e., 8, 9N, 10A, 11A, 12F, 15B, 22F, and 33F). Similarly, serotype 9N showed a significant increase (greater than 50-fold) compared to Prevnar 13.

[0214] Functional Immunogenicity Assay (MOPA)

[0215] Table 6. MOPA titers of 21 serotypes 2 weeks after secondary immunization

[0216]

[0217] With serotypes 1 and 5 and CRM 197 Rabbits immunized with PCV21(3 / 5 / 15B / 22F)-TT also showed a significant increase in functional MOPA titers to each of the eight additional serotypes not present in Prevnar 13 (i.e., 8, 9N, 10A, 11A, 12F, 15B, 22F, and 33F).

[0218] Example 5. Additional details on the preparation of a sugar-protein conjugate from S. pneumoniae serotype 9N

[0219] Preparation of cell banks

[0220] Streptococcus pneumoniae serotype 9N (ATCC 6309) was obtained from the American Type Culture Collection (ATCC). For strain proliferation and removal of animal-derived components, several generations of strain stocks were cultured. The stock vials were stored in a freezer (<-70°C) with synthetic glycerol as a cryopreservative. For the preparation of cell banks, cell cultures were propagated in soy-based medium. Prior to freezing, cells were concentrated by centrifugation, and, after removing the spent medium, the cell pellet was resuspended in fresh medium containing a cryopreservative (e.g., synthetic glycerol).

[0221] Fermentation

[0222] The culture from the cell bank is inoculated into a seed bottle containing a soy-based medium. The culture is incubated at a constant temperature without stirring until growth conditions are met. The culture is inoculated into a seed fermenter containing a soy-based medium using a seed bottle, and the temperature, pH and stirring speed are controlled. The fermentation is terminated after growth stops or the working capacity of the fermenter is reached. After the fermentation is terminated by adding a deactivator, the cell debris is removed using a combination of continuous flow centrifugation and filtration.

[0223] purification

[0224] The pneumococcal polysaccharide purification process consists of multi-layer filtration, repeated concentration / diafiltration and filtration / elution.

[0225] activation

[0226] The final polysaccharide concentration is adjusted to about 2.0 g / L by sequentially adding calculated amounts of WFI. If necessary, the reaction pH is adjusted to about 6.0. After adjusting the pH, the reaction temperature is adjusted to 21-25° C. About 0.024-0.189 mg of sodium periodate is added per 1 mg of sugar to initiate oxidation. The oxidation reaction is carried out at 21-25° C. for 16-20 hours.

[0227] The activated polysaccharide was concentrated and diafiltered using a 100-kDa MWCO ultrafiltration membrane. The diafiltration was performed with 10 volumes of WFI as large as the diafiltration volume. The purified activated polysaccharide was then stored at 2-8°C. The purified activated sugar was characterized by (i) sugar concentration as determined by colorimetric assay, (ii) aldehyde concentration as determined by colorimetric assay, (iii) degree of oxidation, and (iv) molecular weight as measured by SEC-MALLS.

[0228] SEC-MALLS is used to determine the molecular weight of polysaccharides and polysaccharide-protein conjugates. SEC is used to separate polysaccharides based on hydrodynamic volume. A refractive index (RI) detector and a multi-angle laser light scattering (MALLS) detector are used to determine the molecular weight. When light reacts with a substance, the light is scattered. The amount of scattered light is related to the concentration, the square of dn / dc (specific refractive index increment), and the molar mass of the substance. The molecular weight is calculated based on the signal of the scattered light from the MALLS detector and the concentration signal from the RI detector.

[0229] The degree of oxidation (DO) of the activated polysaccharide is determined as the number of moles of sugar repeating units divided by the number of moles of aldehyde. The number of moles of sugar repeating units is determined by various colorimetric techniques, such as the anthrone assay. And, the number of moles of aldehyde is determined by the Park-Jackson colorimetric assay.

[0230] Using the techniques described above, it was determined that the activated S. pneumoniae serotype 9N capsular polysaccharide obtained by the above method had a degree of oxidation of 2-19, more typically 5-10, and a molecular weight of approximately 200-700 kDa.

[0231] Conjugation

[0232] 0.5-2g CRM per 1g activated polysaccharide 197 The ratio of activated polysaccharide to carrier protein CRM 197 Then, the blended mixture is freeze-dried. 197 The freeze-dried mixture was stored at -20 °C.

[0233] Activated polysaccharide and CRM 197 The freeze-dried mixture was reconstituted in 0.1 M sodium phosphate solution and then mixed thoroughly. The final polysaccharide concentration in the reaction solution was about 10-20 g / L. 1.0-1.2 molar equivalents of sodium cyanoborohydride (NaBH 3 CN) was added to the reaction mixture to initiate conjugation, and the reaction was carried out at 35-39° C. for 44-52 hours. The conjugation reaction was terminated by adding a 0.9% sodium chloride solution of the same volume as the conjugation reaction solution, and then 1.8-2.2 molar equivalents of sodium borohydride (NaBH 4 ) to cap the unreacted aldehyde. The capping reaction is carried out at 21-25°C for 3-6 hours.

[0234] The conjugate solution is diluted with 0.9% sodium chloride solution for concentration and diafiltration using a 100-kDa MWCO membrane. The diluted conjugate solution is filtered through a 0.8-0.45 μm filter and purified by concentration and diafiltration. Diafiltration using a 100-kDa MWCO membrane is performed using 15-40 times the diafiltration volume of 0.9% sodium chloride solution. After completing the diafiltration, the remaining solution is filtered through a 0.2 μm filter. The conjugate solution is diluted to a concentration of less than about 0.55 mg / mL, sterile filtered and then stored at 2-8°C.

[0235] The purified serotype 9N conjugate was specifically characterized by (i) protein concentration as determined by colorimetric (Lowry) assay, (ii) aldehyde concentration as determined by colorimetric assay, (iii) sugar to protein ratio, (iv) molecular size distribution as determined by size exclusion chromatography (CL-4B), and (v) molecular weight as measured by SEC-MALLS.

[0236] When varying the degree of oxidation (DO), characteristic changes were observed for the serotype 9N conjugates. The results are summarized in Table 7.

[0237] Table 7

[0238]

[0239] Changes in activated polysaccharides and CRM during freeze drying 197 The characteristic changes of serotype 9N conjugate were observed when the blending ratio was . The results are summarized in Table 8.

[0240] Table 8

[0241]

[0242]

[0243] When the polysaccharide concentration in the conjugation reaction solution was varied, characteristic changes in the serotype 9N conjugates were observed. The results are summarized in Table 9.

[0244] Table 9

[0245]

[0246] Example 6. Analysis of immunogenicity

[0247] Formulated with CRM 197 Monovalent conjugate compositions of conjugated Streptococcus pneumoniae serotype 9N saccharide-protein conjugates.

[0248] The immunogenicity of the monovalent immunogenic compositions of Tables 11-13 was analyzed by ELISA. Serum concentrations of serotype-specific IgG were determined.

[0249] Five female New Zealand white rabbits weighing 2.5-3.5 kg were treated with the recommended human clinical dose (conjugate 2.2 μg; + 0.25 mg / mL aluminum as AlPO 4 ) were immunized via intramuscular route. Rabbits were immunized again with the same dose of conjugate vaccine at week 2 and blood samples were taken at week 4. Serotype-specific ELISA was performed on serum samples at week 0 and week 4.

[0250] The results of the analysis are shown in Table 10. Rabbits immunized with the monovalent conjugate composition (Conjugate No. 8) showed a significant increase in total IgG titers against serotype 9N. Rabbits immunized with the other conjugates also showed a significant increase in total IgG titers.

[0251] Table 10 shows the results of measuring IgG concentration after immunizing rabbits with conjugate No. 8 in Table 8.

[0252] Table 10

[0253]

[0254] Although one or more exemplary embodiments have been described in the specification, those skilled in the art will recognize that various changes in form and details may be made without departing from the spirit and scope of the inventive concept as defined by the following claims.

[0255] References

[0256] The following references are cited in this application and provide general information about the art and provide assays and other details discussed in this application. The following references are incorporated herein by reference in their entirety.

[0257] [1]Prymula et al., The Lancet, 367: 740-48 (2006).

[0258] [2] Vesikari et al., PIDJ, 28(4): S66-76 (2009).

[0259] [3]Dagan et al., Infection & Immunity, 5383-91 (2004).

[0260] [4]Juergens et al., Clinical and Vaccine Immunology, 21(9): 1277-1281(2014).

[0261] [5]Andrews et al., The Lancet, 14: 839-846 (2014).

[0262] [6]Nurkka et al., Vaccine, 20: 194-201 (2001).

[0263] [7] Levin and Stone, J. Immunol., 67: 235-242 (1951).

[0264] [8]WHOManual for the Production and Control of Vaccines: TetanusToxoid, 1977(BLG / UNDP / 77.2Rev.I.)

[0265] [9] Didierlaurent et al., J. Immunol, 183: 6186-6197 (2009).

Claims

1. An immunogenic serotype 9N conjugate comprising a protein carrier conjugated to a capsular polysaccharide from serotype 9N of Streptococcus pneumoniae, wherein the protein carrier is a CRM 197 , and the serotype 9N capsular polysaccharide and CRM 197 Conjugated, the serotype 9N capsular polysaccharide is in an activated state with a degree of oxidation of 2-19 or 5-10 and a molecular weight of 200-700 kDa.

2. The immunogenic serotype 9N conjugate according to claim 1, which has a molecular weight of 500-4000 kDa.

3. The immunogenic serotype 9N conjugate according to claim 1, wherein the serotype 9N capsular polysaccharide in the immunogenic serotype 9N conjugate is bound to the CRM 197 The ratio is 0.1-5 (w / w).

4. The immunogenic serotype 9N conjugate according to claim 3, wherein the serotype 9N capsular polysaccharide in the immunogenic serotype 9N conjugate is bound to the CRM 197 The ratio is 0.5-2.5 (w / w).

5. The immunogenic serotype 9N conjugate according to claim 1, wherein 15-60% of the immunogenic serotype 9N conjugate has a K value measured in a CL-4B column. d 0.3 or less.

6. The immunogenic serotype 9N conjugate according to claim 1, wherein the immunogenic serotype 9N conjugate is prepared using serotype 9N polysaccharide activated to have a degree of oxidation of 2-19.

7. The immunogenic serotype 9N conjugate according to claim 6, wherein the degree of oxidation is 5-10.

8. The immunogenic serotype 9N conjugate according to claim 1, wherein The serotype 9N capsular polysaccharide was mixed with CRM by adding 0.02-0.19 μg periodate per 1 μg of sugar. 197 conjugated, and wherein the immunogenic serotype 9N conjugate has a molecular weight of 500-4000 kDa, a molecular weight distribution of 15-60%, and a K d is 0.3 or lower, and the sugar / protein ratio is 0.5-2.

5.

9. A mixed carrier, multivalent pneumococcal conjugate composition comprising the immunogenic serotype 9N conjugate according to any one of claims 1-8.

10. The mixed carrier, multivalent pneumococcal conjugate composition of claim 9, further comprising an adjuvant.

11. A method for preparing an immunogenic conjugate of Streptococcus pneumoniae serotype 9N, the method comprising: (a) lysing bacterial cells which produce Streptococcus pneumoniae serotype 9N capsular polysaccharide by fermentation; (b) purifying S. pneumoniae serotype 9N capsular polysaccharide from lysed bacterial cells; (c) activating the capsular polysaccharide of Streptococcus pneumoniae serotype 9N by reacting it with an oxidizing agent to achieve a degree of oxidation of 2-19 or 5-10; as well as (d) Activated pneumococcal serotype 9N capsular polysaccharide and CRM 197 Mixing forms the immunogenic serotype 9N-conjugate.

12. The method according to claim 11, wherein the CRM mixed in step (d) 197 Reaction with a reducing agent to form a conjugate with activated S. pneumoniae serotype 9N capsular polysaccharide.

13. The method according to claim 11, wherein in step (c), 0.02-0.19 μg of periodate is reacted with 1 μg of S. pneumoniae serotype 9N capsular polysaccharide at 20-25°C for 15-20 hours.

14. The method of claim 11, wherein the capsular polysaccharide of Streptococcus pneumoniae serotype 9N reacted with the oxidizing agent in step (c) has a molecular weight of 400-900 kDa.

15. The method of claim 11, wherein in step (d) 197 The molecular weight of the mixed activated S. pneumoniae serotype 9N capsular polysaccharides is 200-700 kDa.

16. The method of claim 11, wherein the immunogenic serotype 9N conjugate formed in step (d) has a molecular weight of 500-4000 kDa.

17. The method according to claim 11, wherein CRM 197 The initial input ratio with activated serotype 9N capsular polysaccharide is 0.5-2.5:

1.

18. The method of claim 11, wherein at least 15-60% of the immunogenic serotype 9N conjugate has a K value measured in a CL-4B column. d 0.3 or less.

19. The method according to any one of claims 11 to 18, wherein in step (c), 0.02-0.19 μg of periodate is reacted with 1 μg of S. pneumoniae serotype 9N capsular polysaccharide, and wherein the immunogenic serotype 9N conjugate formed in step (d) has a molecular weight of 500-4000 kDa, a molecular weight distribution of 15-60%, and a K value measured on a CL-4B column of 0.05-0.10 μg. d is 0.3 or lower, CRM 197 / polysaccharide ratio is 0.5-2.

5.

20. The method according to any one of claims 11-18, wherein the degree of oxidation is 5-10.